KR100990710B1 - Composition comprising herbal mixture extract as an active ingredient for prevention and treatment of alcohol dependence - Google Patents
Composition comprising herbal mixture extract as an active ingredient for prevention and treatment of alcohol dependence Download PDFInfo
- Publication number
- KR100990710B1 KR100990710B1 KR1020070126128A KR20070126128A KR100990710B1 KR 100990710 B1 KR100990710 B1 KR 100990710B1 KR 1020070126128 A KR1020070126128 A KR 1020070126128A KR 20070126128 A KR20070126128 A KR 20070126128A KR 100990710 B1 KR100990710 B1 KR 100990710B1
- Authority
- KR
- South Korea
- Prior art keywords
- alcohol
- extract
- rats
- pomc
- mrna
- Prior art date
Links
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 63
- 239000000284 extract Substances 0.000 title claims abstract description 59
- 201000007930 alcohol dependence Diseases 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 239000004480 active ingredient Substances 0.000 title claims abstract description 16
- 230000002265 prevention Effects 0.000 title abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 207
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 claims abstract description 71
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims abstract description 71
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 61
- 230000014509 gene expression Effects 0.000 claims abstract description 25
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 210000004207 dermis Anatomy 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 9
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 9
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 9
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 9
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 9
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 9
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 9
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 9
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 9
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 239000012676 herbal extract Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 6
- 235000008434 ginseng Nutrition 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 5
- 235000002789 Panax ginseng Nutrition 0.000 claims description 4
- 235000014676 Phragmites communis Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims 4
- 244000273256 Phragmites communis Species 0.000 claims 2
- 244000000231 Sesamum indicum Species 0.000 claims 2
- 235000003434 Sesamum indicum Nutrition 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 235000008216 herbs Nutrition 0.000 claims 2
- 241000208340 Araliaceae Species 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 57
- 241000411851 herbal medicine Species 0.000 abstract description 24
- 230000002269 spontaneous effect Effects 0.000 abstract description 13
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 235000019788 craving Nutrition 0.000 abstract description 5
- 241000361919 Metaphire sieboldi Species 0.000 abstract description 3
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 68
- 241000700159 Rattus Species 0.000 description 61
- 241000699670 Mus sp. Species 0.000 description 37
- 230000035622 drinking Effects 0.000 description 22
- 101800005049 Beta-endorphin Proteins 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 18
- 210000003016 hypothalamus Anatomy 0.000 description 18
- 102400000748 Beta-endorphin Human genes 0.000 description 17
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 16
- 230000001476 alcoholic effect Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 229940124595 oriental medicine Drugs 0.000 description 9
- 108010041071 proenkephalin Proteins 0.000 description 9
- 241001092040 Crataegus Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- 102100038931 Proenkephalin-A Human genes 0.000 description 6
- 244000251905 Pseudocydonia sinensis Species 0.000 description 6
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 5
- 108010049140 Endorphins Proteins 0.000 description 5
- 102000009025 Endorphins Human genes 0.000 description 5
- 240000004371 Panax ginseng Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000001784 detoxification Methods 0.000 description 5
- 238000001647 drug administration Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000002267 hypothalamic effect Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229910052733 gallium Inorganic materials 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000008338 local blood flow Effects 0.000 description 4
- 229960002715 nicotine Drugs 0.000 description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000895481 Homo sapiens Corticoliberin Proteins 0.000 description 3
- 206010021567 Impulsive behaviour Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108010008364 Melanocortins Proteins 0.000 description 3
- 108010093625 Opioid Peptides Proteins 0.000 description 3
- 102000001490 Opioid Peptides Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- PNMZQWKBJIQQJL-FAUHKOHMSA-N chembl440057 Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)C1=CNC=N1 PNMZQWKBJIQQJL-FAUHKOHMSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000005153 frontal cortex Anatomy 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002865 melanocortin Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000051367 mu Opioid Receptors Human genes 0.000 description 3
- 239000003399 opiate peptide Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 108020001612 μ-opioid receptors Proteins 0.000 description 3
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000219495 Betulaceae Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 102400000744 Melanotropin gamma Human genes 0.000 description 2
- 101800000520 Melanotropin gamma Proteins 0.000 description 2
- 206010057852 Nicotine dependence Diseases 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 235000004789 Rosa xanthina Nutrition 0.000 description 2
- 241000220222 Rosaceae Species 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000025569 Tobacco Use disease Diseases 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- -1 am-phetamine Chemical compound 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 235000011869 dried fruits Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000037195 reproductive physiology Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- OBBCRPUNCUPUOS-UHFFFAOYSA-N tectorigenin Chemical compound O=C1C2=C(O)C(OC)=C(O)C=C2OC=C1C1=CC=C(O)C=C1 OBBCRPUNCUPUOS-UHFFFAOYSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- GZWUQPQBOGLSIM-VOOUCTBASA-N γ msh Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C(C)C)C1=CC=C(O)C=C1 GZWUQPQBOGLSIM-VOOUCTBASA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ISTWCKNDZOSMPU-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[(9-hydroxy-4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl)oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4)C)(C)CC3)(C)CC2)(C)C)OC(CO)C(O)C1O ISTWCKNDZOSMPU-UHFFFAOYSA-N 0.000 description 1
- QTVAYNGFFDZGDR-CIJVEFAYSA-N 5-hydroxy-6-methoxy-3-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)O3)O)=C(OC)C(O)=C2C1=O QTVAYNGFFDZGDR-CIJVEFAYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 241000219496 Alnus Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000141218 Alpinia officinarum Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 description 1
- 241000132011 Atractylodes lancea Species 0.000 description 1
- 240000000724 Berberis vulgaris Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 1
- 241000657480 Crataegus pinnatifida Species 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 241000234646 Cyperaceae Species 0.000 description 1
- 241000234653 Cyperus Species 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000002111 Eye Abnormalities Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 235000008586 Hovenia Nutrition 0.000 description 1
- 241000405398 Hovenia Species 0.000 description 1
- 244000010000 Hovenia dulcis Species 0.000 description 1
- 235000008584 Hovenia dulcis Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- BGMQZCQIGJVTOI-UHFFFAOYSA-N Kaikasaponin III Natural products CC1OC(OC2C(O)C(O)C(CO)OC2OC3C(O)C(O)C(OC3OC4CCC5(C)C(CCC6(C)C5C=CC7C8CC(C)(C)CC(O)C8(C)CCC67C)C4(C)C)C(=O)O)C(O)C(O)C1O BGMQZCQIGJVTOI-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101150093308 POMC gene Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 description 1
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000001774 alpinia officinarum Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000003295 arcuate nucleus Anatomy 0.000 description 1
- PQKHESYTSKMWFP-WZJCLRDWSA-N beta-Funaltrexamine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3NC(=O)/C=C/C(=O)OC)CN2CC1CC1 PQKHESYTSKMWFP-WZJCLRDWSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 241001233061 earthworms Species 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229960002520 hepatitis vaccine Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- MYJXWCIZOOKQLK-UHFFFAOYSA-N kakkalide Natural products COc1cc2C(=O)C(=COc2cc1OC3OC(COC4OCC(O)C(O)C4O)C(O)C(O)C3O)c5ccc(O)cc5 MYJXWCIZOOKQLK-UHFFFAOYSA-N 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- UYLQOGTYNFVQQX-UHFFFAOYSA-N psi-tectorigenin Natural products COC1=C(O)C=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 UYLQOGTYNFVQQX-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010085082 sigma receptors Proteins 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- OYUJPVCKGSEYDD-UHFFFAOYSA-N tectorigenin Natural products COc1c(O)cc2OCC(C(=O)c2c1O)c1ccc(O)cc1 OYUJPVCKGSEYDD-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
본 발명은 혼합 생약재 추출물을 유효성분으로 하는 알코올 의존증의 예방 및 치료용 조성물에 관한 것으로서, 보다 구체적으로는 항갈망 효과를 가지는 갈화와 지구자를 포함한 혼합 생약재 추출물을 유효성분으로 하는 알코올 의존증의 예방 및 치료용 조성물에 관한 것이다. 본 발명의 혼합 생약재 추출물을 포함하는 조성물은 자발적 알코올 섭취와 관련된 POMC mRNA의 발현을 감소시켜 알코올의 섭취를 막음으로써 알코올 의존증의 예방 및 치료에 유용하게 이용될 수 있다. The present invention relates to a composition for the prevention and treatment of alcohol dependence using the mixed herbal medicine extract as an active ingredient, and more specifically to the prevention of alcohol dependence using the mixed herbal medicine extract including browning and earthworm having an anti- craving effect as an active ingredient and A therapeutic composition. The composition comprising the mixed herbal medicine extract of the present invention can be usefully used for the prevention and treatment of alcohol dependence by reducing the expression of POMC mRNA associated with spontaneous alcohol intake to prevent alcohol intake.
Description
본 발명은 혼합 생약재 추출물을 유효성분으로 하는 알코올 의존증의 예방 및 치료용 조성물에 관한 것으로서, 보다 구체적으로는 항갈망 효과를 가지는 갈화와 지구자를 포함한 혼합 생약재 추출물을 유효성분으로 하는 알코올 의존증의 예방 및 치료용 조성물에 관한 것이다. The present invention relates to a composition for the prevention and treatment of alcohol dependence using the mixed herbal medicine extract as an active ingredient, and more specifically to the prevention of alcohol dependence using the mixed herbal medicine extract including browning and earthworm having an anti- craving effect as an active ingredient and A therapeutic composition.
알코올 의존증(alcohol dependence)이란 알코올 결여 시의 불쾌감을 피하기 위하여 지속적 또는 주기적으로 음주하고 싶다는 강박적 욕구가 항상 있고 알코올 과잉 반복섭취의 결과 여러 종류의 정신적, 신체적 및 사회적 장애를 일으키는 것을 말한다. Alcohol dependence means that there is always an obsessive desire to drink continuously or periodically to avoid discomfort in the absence of alcohol and that causes various types of mental, physical and social disorders as a result of excessive alcohol intake.
한국보건사회연구원에 의하면 2001년 우리나라 남자 26.1%, 여자 10.5%, 성인 전체의 20.9%가 알코올 의존상태라고 한다. 이것은 성인 5명 중 1명이 알코올 의존 상태라는 것으로 이로 인한 사회적 문제와 소요비용이 증가하고 있다.According to the Korea Institute for Health and Social Affairs, in 2001, 26.1% of males, 10.5% of females, and 20.9% of all adults were alcohol dependent. This suggests that one in five adults is alcohol dependent, increasing social problems and costs.
한의학에서는 알코올 의존증과 관련하여 『황제내경영추(黃帝內經靈樞)』, 『제병원후론(諸病源候論)』, 『본초강목(本草綱目)』, 『증집의방신편(增輯醫方新編)』 등과 같은 고전문헌에 알코올 의존의 의존적 행동, 정신 증상, 신체적 증상 등이 서술되어 있으며, 현대 임상적으로는 갈근해주탕(葛根解酒湯), 창이자(蒼耳子)로 구성된 단주화(斷酒丸), 갈화(갈화)와 지구자로 구성된 해주지갈탕(解酒枳葛湯), 견우자(牽牛子), 갈근(葛根), 인진(茵蔯), 진피(陳皮), 양강(良薑), 적봉령(赤茯笭), 초두구(草豆寇) 등으로 구성된 성주청간탕(醒酒淸肝湯) 등이 사용된다. 이를 바탕으로 최근에는 한약물의 알코올중독 치료 효과에 관한 다양한 연구들이 이루어지고 있다. In Oriental Medicine, in relation to alcohol dependence, Emperor Inchuchu (黄 병), 『Che hospital Furon』, 『Checho Kang-mok』, 『Cultivation of Bangshin-pyeon (增 輯 醫) Classical texts such as 方 新 』, etc. describe the dependence of alcohol dependence, mental symptoms, and physical symptoms, and in modern clinical practice, it is composed of Galgunju-tang (탕 根 解酒 湯) and Chang-za (자 子). Hajujigalang, Haeunji Galtang (견 酒 丸), Galhwa (Gulhwa) and Earth's Earth, Geunja, Gal Geun, Injin, Jinpi, Yanggang ), Seongjucheonggantang (醒酒 淸 肝 湯) consisting of Red Bongryong (赤 茯 笭) and Chodugu (豆寇 구) are used. Recently, various studies have been conducted on the effects of the herbal medicine on alcoholism.
한은 알코올중독증을 유발시킨 흰쥐에 해주지갈탕 등을 투여하여 GOT, GPT, TG 등의 유의한 변화를 보고하였으며(한경승, 김지혁, 황의완 : 해주지갈탕, 단주환 및 성주청간탕이 실험적 Alcoholism에 미치는 영향, 경희대학교 대학원, p.44, 1992), 방은 알코올중독증을 유발시킨 생쥐에 갈근해주탕 합 단주환(葛根解酒湯 合 斷酒丸) 및 해주지갈탕을 투여하여 Food-step수, Rearing 횟수, Rota-Rod에 의한 운동실조(motor incoordination)의 변화, 수중 T-미로 통과시간의 변화를 대조군과 비교하여 유의성있는 변화를 관찰하였고(방혜연, 황의완 : 葛根解酒湯 合 斷酒丸과 해주지갈탕이 실험적 알코올리즘 생쥐의 행동에 미치는 영향, 동의신경정신과학회지,5(1) : 93-101, 1994 , 긍은 갈근 추출물 및 그 주요 추출 성분인 다이드제인, 다이진(daidzin)이 에탄올을 선호하는 Syrian Golden 햄스터의 에탄올 섭취를 감소 시킨다고 보고하였으며(Keung Wing-Ming, Vallee Bert L. : Daidzin and daidzein suppress free-choice ethanol intake by Syrian Golden hamsters, Proc. Natl. Acad. Sci,USA, pp.10008-100012, 1993), 오버스트리트는 갈근과 감귤(Citrus Reticulata)혼합추출물과 갈근 추출물이 P 랫트, Fawn-Hooded 랫트(알코올 선호 랫트)의 알코올 섭취량을 감소시키고(Overstreet DH, Lee YW, Rezvani AH, Pei YH, Criswell HE, Janowsky DS : Suppression of alcohol intake after administration of the Chinese herbal medicine, NPI-028, and its derivatives, Alcohol Clin Exp Res, 20(2) : 221-227, 1996), 알코올 금단 증상을 감소시켰으며, Giancarlo은 단삼(Salvia miltiorrhiza) 추출물이 에탄올을 선호하는 sP 랫트(Sardinian 알코올 선호 랫트)의 에탄올 섭취량과 선호도를 억제시키는 것을 보고하였으며(Giancarlo Colombo, Roberta Agabio, Carla Lobina, Roberta Reali, Paolo Morazzoni, Ezio Bombardelli and Gian Luigi Gessa : Salvia miltiorrhiza Extract Inhibits Alcohol Absorption, Preference, and Discrimination in sP Rats, Alcohol, 18(1) : 65-70, 1999), 임상 시험에 있어서도 윤은 갈근이 급성 주정중독 상태 및 금단상태에서 회복된 28세부터 59세 남자 환자들의 음주욕구를 감소시키며(윤종태, 김명정, 김성곤 : 갈근의 장기투여가 주정중독 환자의 음주욕구에 미치는 영향, 신경정신의학, 34(6) : 1937-1948, 1995), 김은 정상인과 알코올 의존 환자에서 갈근이 혈중 알코올 농도를 상승시키지 않는다고 하였다(김지훈, 김명정, 김성곤, 박제민, 정영인 : 정상 성인에서 갈근(Radix puerariae)의 장기투여가 혈중 알콜 농도에 미치는 영향, 신경정신의학, 35(6) : 1230-1235, 1996; 김명정, 정영인, 박제 민, 김성곤, 최영길 : 알코올 의존 환자에서 갈근이 혈중 알코올 농도와 음주 효과에 미치는 영향, 신경정신의학, 35(6) : 1236-1246, 1996). 강 등은 갈근이 기초 음주 욕구를 감소시키고 음주 후에 유발되는 알코올 갈망의 증가를 차단한다고 하였다(강철중, 김명정, 김성곤, 김인주 : 알코올 의존환자에서 갈근이 알코올 갈망과 대뇌 국소혈류량의 변화에 미치는 영향, 신경정신의학, 36(5) : 861-869, 1997). Han-eun reported that GOT, GPT, and TG were significantly changed by administering Haejuji-galtang to alcohol-induced rats. Kyung Hee University Graduate School, p.44, 1992), Bang, Geunjuju-tang, Junjuhwan and Hajujigaltang, were administered to mice with alcoholism. The changes in motor incoordination by Rota-Rod and the transit time of T-maze in water were compared with those of the control group (Bye Hye-yeon, Hwang Eon-wan: 葛根 解酒 湯 合 酒 酒 丸 and Hajijigaltang). The Effects of Experimental Alcoholism on the Behavior of Mice, Journal of Oriental Neuropsychiatry, 5 (1): 93-101, 1994, Yeong-Jeun Lee, the root extract and its major extract, Dyeze, Syrian Golden Hams (Keung Wing-Ming, Vallee Bert L .: Daidzin and daidzein suppress free-choice ethanol intake by Syrian Golden hamsters, Proc. Natl. Acad. Sci, USA, pp. 10008-100012, 1993), Overstreet found that a mixture of root and citrus reticulata extract and root extract reduced alcohol intake in P rats, Fawn-Hooded rats (alcohol preferred rats) (Overstreet DH, Lee YW, Rezvani AH, Pei YH, Criswell HE, Janowsky DS: Suppression of alcohol intake after administration of the Chinese herbal medicine, NPI-028, and its derivatives, Alcohol Clin Exp Res, 20 (2): 221-227, 1996). , Giancarlo reported that Salvia miltiorrhiza extract inhibited the ethanol intake and preference of sP rats (Sardinian alcohol preferred rats) who prefer ethanol (Giancarlo Colombo, Roberta Agabio, Carla Lobina, Roberta Reali, Paolo Morazzoni, Ezio). Bomba rdelli and Gian Luigi Gessa: Salvia miltiorrhiza Extract Inhibits Alcohol Absorption, Preference, and Discrimination in sP Rats, Alcohol, 18 (1): 65-70, 1999), Reduction of Drinking Desire in Male Patients Recovered from 28 to 59 Years (Jong-Tae Yoon, Myung-Jung Kim, and Sung-Kon Kim: The Effect of Long-term Dose of Brown Root on Drinking Desire of Alcoholic Patients, Neuropsychiatric, 34 (6): 1937-1948 , 1995), Kim stated that reed does not raise blood alcohol levels in normal and alcohol-dependent patients (Kim Ji-hoon, Kim Myung-jeong, Kim Seong-gon, Park Je-min, and Young-in Chung: Long-term administration of radix puerariae on blood alcohol levels in normal adults). Impact, Neuropsychiatry, 35 (6): 1230-1235, 1996; Kim, Myung-Jung, Young-In Chung, Je-Min Park, Seong-Kon Kim, and Young-Gil Choi: The Effect of Brown Root on Blood Alcohol Concentration and Drinking Effect in Alcohol-Dependent Patients, Neuropsychiatric Medicine, 35 (6): 1236-1246, 1996). Kang et al. Reported that rooting reduces the desire for basic drinking and blocks the increase in alcohol cravings induced after drinking (Cheol-Joong, Kim Myung-Jung, Sung-Kon Kim, and In-Ju Kim: Effects of Browning on Alcohol Craving and Cerebral Local Blood Flow in Alcohol-Dependent Patients, Neuropsychiatry, 36 (5): 861-869, 1997).
알코올 의존증의 원인은 에탄올이 도파민을 비롯한 신경전달물질 시스템의 이상으로, 보상작용의 이상(reward system dysfunction)이 에탄올의 대한 내성, 강화를 일으켜, 결국 알코올에 대한 음주욕구(cravings)가 나타나 의존이 나타나는 것으로 알려져 왔다(Sanchis-Segura C, Grisel JE, Olive MF, Ghozland S, Koob GF, Roberts AJ, Cowen MS : Role of the Endogenous Opioid System on the Neuropsychopharmacological Effects of Ethanol: New Insights About an Old Question, Alcohol Clin Exp Res, 29(8) : 1522-1527, 2005). 이런 알코올 의존을 일으키는 기전으로 베타-엔돌핀의 전구물질인 POMC(proopiomelanocortin)가 내인성 아편계 물질체계(Endogenous Opioid system, EOPS)에서 중요한 역할을 하는데, 알코올을 좋아하는 정도가 높으면 시상하부의 POMC mRNA 레벨이 높고, 시상하부에서의 내인성 아편계 펩티드인 베타-엔돌핀의 유리를 증가시키는 것으로 알려져 있다. 증가된 베타 엔돌핀은 아편계 물질 수용체(opioid receptors)의 결합처를 변화시켜 EOPS의 보상작용으로 강화효과(reinforc-ing effects)를 나타낸다고 알려져 있다. 이렇게 발생하는 알코올 음주욕구를 치료하기 위해, 날트렉손과 같은 약물은 아편 계물질 길항제로서 작용하여 음주욕구를 감소시킨다고 연구되었다. 그런데, 한약물의 연구에 있어 효능에 대한 연구는 제한적으로 있었으나, 항갈망 기전 연구는 지금까지 없는 실정이다.The cause of alcohol dependence is that ethanol is an abnormality of neurotransmitter system including dopamine, and the reward system dysfunction causes ethanol resistance and strengthening, which eventually leads to alcohol cravings. Sanchis-Segura C, Grisel JE, Olive MF, Ghozland S, Koob GF, Roberts AJ, Cowen MS: Role of the Endogenous Opioid System on the Neuropsychopharmacological Effects of Ethanol: New Insights About an Old Question, Alcohol Clin Exp Res, 29 (8): 1522-1527, 2005). The alcohol-induced mechanism is a precursor of beta-endorphin, POMC (proopiomelanocortin), which plays an important role in the endogenous Opioid system (EOPS). This high, hypothalamus is known to increase the release of beta-endorphin, an endogenous opiate peptide. Increased beta endorphins are known to exhibit reinforc-ing effects by compensating EOPS by altering the binding sites of opioid receptors. In order to treat this alcoholic craving, it has been studied that drugs such as naltrexone act as opiate antagonists and reduce the craving. However, there have been limited studies on the efficacy of herbal medicines, but there is no research on the anti- longing mechanism.
본 발명에서 사용한 갈근해주탕은 한의학 임상에서 알코올중독 환자에게 사용되어 경험적 효과가 밝혀진 갈근해주탕 원방((경희대학교 한의과대학 부속한방병원 : 경희한방처방집, 경희의료원, 서울, p.533, 1997)에 해주독의 효능이 있는 지구자를 첨가한 것이다. Gal Geunjujutang used in the present invention was used in alcohol clinical trials in patients with alcoholism, Gal Geunjujuwon Wonbang (Dept. of Oriental Medicine Hospital, Kyung Hee University College of Oriental Medicine: Kyung Hee Oriental Medicine Prescription, Kyung Hee Medical Center, Seoul, p.533, 1997) To add the earth's potency of Haedogdogok.
갈근해주탕 원방의 알코올중독에 대한 연구로는 갈근해주탕과 지구자와 갈화로 구성된 해주지갈탕의 알코올중독에 미치는 효능을 입증하고자 Foot-step수, Rearing 횟수, Rota-Rod에 의한 운동실조의 변화, 수중 T-미로 통과시간의 변화 등 알코올리즘 생쥐의 행동을 관찰한 연구에서 Foot-step수의 변화는 갈근해주탕은 8시간에서 대조군에 비하여 유의성 있는 감소를 보였고, Rearing 횟수의 변화는 갈근해주탕 투여군이 3시간과 8시간에서 대조군에 비하여 유의성 있는 변화를 보였고 해주지갈탕 투여군은 8시간에서 유의성 있는 변화를 보였다. Rota-Rod에 의한 운동실조의 변화에서는 갈근해주탕 투여군이 8시간에서 유의성 있는 완화를 보였고, 수중 T-미로 성공횟수의 변화는 증가 경향을 보였다. 수중 T-미로 통과시간의 변화는 갈근해주탕 투여군이 8시간에서 유의성있는 감소를 보였으며(李時珍 : 本草綱目, 人民衛生出版社, 北京, pp.798, 862, 1277, 1577, 1558, 1718, 1982), 해주지갈탕의 알코올 중독에 미치는 효능을 알아보고자 흰쥐에게 실험적 알코올리즘을 유발시킨 후 실험한 결과, 벽 기어오르기 시간이 해주지갈탕에서 5시간과 8시간에서 대조군에 비해 유의성 있는 증가를 보여(한경승, 김지혁, 황의완 : 해주지갈탕, 단주환 및 성주청간탕이 실험적 알코올 중독에 미치는 영향, 경희대학교 대학원, p.44, 1992) 알코올중독으로 인한 공간지각 능력의 감퇴를 완화시키는 효능을 보여주었다. The study on alcoholism of galgejuju-tang far-field was conducted to demonstrate the effects on the alcoholism of galgejuju-tang, Hajujigaltang, which consists of earth and gallium, and changes in ataxia due to the number of foot-steps, rearing, and Rota-Rod. In the study of the behavior of alcoholism mice such as the change of T-maze time in the water, the change in the number of foot-steps showed a significant decrease in Galgeju-tang in 8 hours compared to the control, and the change in the number of rearing was The treatment group showed significant change in 3 hours and 8 hours compared to the control group, and the Hajujigaltang group showed significant change in 8 hours. In the change of ataxia induced by Rota-Rod, the Galgeju-tang administration group showed significant relief at 8 hours, and the change in the number of successes of T-maze in the water tended to increase. Changes in the time of T-maze in water showed a significant decrease at 8 hours in the Galgeju-tang administration group (李 時珍: 本草綱目, 人民 衛生 出版社, 北京, pp.798, 862, 1277, 1577, 1558, 1718, 1982), after experimenting with experimental alcoholism in rats to investigate the effects of haejugaltang on alcoholism, the wall climbing time showed a significant increase in the haejugaltang in 5 and 8 hours compared to the control group (Han Kyung-seung) , Ji-Hyuk Kim, Eui-Whan Hwang: Haejigaltang, Danjuhwan, and Seongjucheonggantang, and their effects on experimental alcoholism, Graduate School of Kyung Hee University, p.44, 1992), have shown efficacy in alleviating the decline of spatial perception ability due to alcoholism.
본 처방에 구성된 갈근(Radix Puerariae)은 두과(Leguminosae)에 속한 다년생 낙엽등본식물(落葉藤本植物)인 칡의 뿌리로써 학명은 Pueraria thunbergiana B.이다. 갈근의 효능은 해주독, 발한해기(發汗解肌), 발표투진(發表透疹), 생진지갈(生津止渴), 해독배농(解毒排膿), 승양지사(升陽止瀉) 등의 작용이 있어 임상적으로는 감기, 구토, 홍역, 소갈, 설사, 협심증, 고혈압, 편두통, 망막동맥폐색증, 돌발성이롱(突發性耳聾), 알코올중독증에 많이 활용되어 왔다. Radix Puerariae is a root of the perennial deciduous plant of Leguminosae. The name is Pueraria thunbergiana B. The effects of reed roots include Haedogok, sweat sweating, presentation jinjin, Saengjinjigal, detoxification, and booster. Clinically, it has been widely used for colds, vomiting, measles, sputum, diarrhea, angina, hypertension, migraine, retinal artery occlusion, sudden elongation, and alcoholism.
갈근의 장기 투여가 음주 효과에 미치는 영향은 알코올 의존으로 입원하여 급성주정중독 상태 및 금단상태에서 회복된 남자 환자를 대상으로 갈근 투여군과 위약투여군으로 나누어 4주간 투여한 결과 갈근 투여 전에 비하여, 음주 후 수축기 혈압은 음주 후 10, 30, 60, 90분에서 그리고 이완기 혈압은 음주 후 10, 30, 60, 90, 120분에서 유의하게 낮았다. 갈근 투여 전의 수축기 혈압은 음주 후 10분에서그리고 이완기 혈압은 음주 후 10, 30, 60분에서 음주 전에 비해 유의하게 상승하였으나 갈근 투여 후에는 알코올에 의한 우의 혈압상승 효과가 차단되었다. 갈근 투여 전에 비하여 투여 후에 운동량은 음주 후 60, 90분에서 유의하게 낮았고 목소리는 음주 후, 10,30, 60, 90분에서 유의하게 작았다(김명정, 정영인, 박제민, 김성곤, 최영길 : 알코올 의존 환자에서 葛根이 혈중 알코올 농도와 음주 효과에 미 치는 영향, 신경정신의학, 35(6) : 1236-1246, 1996 ). The effect of long-term administration of carpal root on the alcoholic effect of male patients who were hospitalized due to alcohol dependence and recovered from acute alcoholism and withdrawal was divided into 4 groups for the treatment of carpal root and placebo for 4 weeks. Systolic blood pressure was significantly lower at 10, 30, 60, 90 minutes after drinking and diastolic blood pressure at 10, 30, 60, 90, 120 minutes after drinking. The systolic blood pressure before the rooting was significantly increased at 10 minutes after drinking and the diastolic blood pressure was 10, 30, and 60 minutes after drinking. The amount of exercise was significantly lower at 60, 90 minutes after drinking and the voice was significantly lower at 10, 30, 60, 90 minutes after drinking (Kim, Myung-Jung, Young-In Chung, Je-Min, Kim, Seong-Kon, and Young-Gil Choi). Effects of Roots on Blood Alcohol Concentration and Drinking Effects in Neuropsychiatry, 35 (6): 1236-1246, 1996).
급성 주정중독 상태 및 금단상태에서 회복된 28세부터 59세의 남자환자들 중 Short Michigan Alcoholism Screening Test의 13문항 중 4문항 이상, CAGE의 4문항 중 2문항 이상 해당자 64명을 대상으로 위약군, 갈근 2 g투여군(아침, 저녁으로 1g씩), 갈근 4 g(아침, 저녁으로 2 g 씩) 투여군의 3군으로 무작위 배정하여 매일 4주간 연속 투여하여 Likert Scale 및 VAS를 이용하여 음주욕구를 측정한 연구에서는, 갈근 투여군에서 음주욕구의 유의한 감소가 보였다(윤종태, 김명정, 김성곤 : 葛根의 장기투여가 주정중독 환자의 음주욕구에 미치는 영향, 신경정신의학,34(6) : 1937-1948, 1995). Of the 28 to 59-year-old male patients recovering from acute alcoholism and withdrawal, the placebo group included 64 subjects with at least 4 out of 13 questions in the Short Michigan Alcoholism Screening Test and at least 2 out of 4 questions with CAGE. Randomly assigned to 3 groups of 2g dose group (1g for morning and evening) and 4g (2g each for morning and evening), and administered for 4 weeks daily to measure drinking desire using Likert Scale and VAS. In one study, there was a significant decrease in the desire for drinking in the group of the roots (Yong, Jong-Tae, Myung-Jung Kim, and Sung-Kon Kim: The effect of long-term administration on the drinking habits of alcoholic patients, Neuropsychiatric, 34 (6): 1937-1948, 1995).
알코올 중독으로 입원하여 급성중독과 금단증상에서 회복된 환자 5명을 대상으로, 알코올 갈망, 불안 및 기분을 VAS로 측정하여 기초 알코올 갈망의 수준을 가늠하고 SPECT(단일광자방출전산화단층촬영술)를 이용하여 양측 미상핵 두부, 양측 시상 및 양측 안와전두엽의 국소 혈류량을 측정하여, 건조 갈근 과립 복용이 알코올 음료 섭취 후 나타나는 갈망과 두뇌의 국소 혈류량에 미치는 변화를 관찰한 연구에서는, 갈근이 알코올 중독환자에서 기초 음주 욕구를 감소시키고, 음주 후에 유발되는 알코올 갈망의 증가를 차단하며, 이러한 음주욕구의 변화와 변연계, 선조체 특히 미상핵의 국소 혈류량의 변화 사이에 의미있는 연관성이 존재할 것으로 시사된다고 하였다(강철중, 김명정, 김성곤, 김인주 : 알코올 의존환자에서 葛根이 알코올 갈망과 대뇌 국소혈류량의 변화에 미치는 영향, 신경정신의학, 36(5) : 861-869, 1997). In five patients who were hospitalized for alcoholism and recovered from acute poisoning and withdrawal symptoms, alcohol craving, anxiety, and mood were measured by VAS to assess the level of basic alcohol craving and to use SPECT (single photon emission computed tomography). Local blood flow in bilateral caudate head, bilateral thalamus, and bilateral orbital frontal lobe was measured to determine the effects of dry root granules on craving and brain local blood flow after alcohol intake. It is suggested that there is a significant association between the change in drinking desire and the change of local blood flow in the limbic system and striatum, especially the unknown nucleus. Sung-Gon Kim and In-Ju Kim: Alcohol Craving and Cerebral Soup in Alcohol-Dependent Patients Effect of changes in blood flow, nerve Psychiatry, 36 (5): 861-869, 1997).
본 발명에 주요 구성된 갈화(puerariae Flos)는 두과(Leguminosae)에 속한 다년생 낙엽등목인 칡(Pueraria thunbergiana B.)의 꽃을 건조한 것으로 해주독의 효능이 현저하며 주치증상(醒胃止渴)의 작용을 하여, 임상에서 음주과도, 구갈, 위기손상(胃氣損傷) 등의 증상을 치료하여 간기능 회복에 널리 활용되고 있다.Puerariae Flos composed mainly in the present invention dried flowers of the perennial deciduous tree (Pueraria thunbergiana B.) belonging to the legumes (Leguminosae), the efficacy of the poison is remarkable and the effect of the main symptoms (醒胃 止渴) It is widely used in the recovery of liver function by treating the symptoms such as drinking excessive, dry mouth, crisis damage (胃氣 損傷) in the clinical.
갈화에 대한 연구로는 쥐의 혈액, 뇌 및 간의 에탄올 농도를 유의있게 감소시켰으며, 갈화로부터 분리된 텍토리제닌(tectorigenin)과 가이카사포닌(kaikasaponin) Ⅲ는 아급성 알코올 중독된 흰쥐 간의 자유 라디칼 생성계 효소를 억제시켜 알코올로 인한 간손상을 회복시키고, 알코올 대사 효소계에 관여하여 해독작용에 영향을 미쳤다. 갈화 성분인 카카라이드(Kakkalide) 및 그 대사체 성분들이 마우스에서의 혈중 알코올 농도 억제 효과가 나타났으며(한여옥 : 갈화 성분인 Kakkalide 및 그 대사체의 mouse에서의 혈중 알콜농도 억제 효과와 그 대사 효소의 부분 분리 정제, 경희대학교 대학원, 2002), 메탄올 추출액, 이소플라보노이드 분획, 트리테르페노이드 사포닌 분획 등의 갈화추출물이 혈중알코올 및 아세트알데히드의 농도에 미치는 영향과 알코올로 유발된 대사과정 및 간기능에 미치는 영향에 대하여 연구하여 갈화의 알코올 해독효과가 나타났으며(Niiho Y, Yamazaki T, Nakajima Y, Itoh H, Takeshita T, Kinjo J, Nohara T. : Pharmacological studies on puerariae flos. : Ⅰ. The effects of pu-erariae flos on alcoholic metabolism and spontaneous movement in mice, Yakugaku Zasshi, 109(6) : 424-431, 1989), 갈화 약침이 알코올 중독 흰쥐의 치상회에서 더 많은 신경세포를 생성 시키는 것으로 나타났다(서정철, 김이화, 장미현, 김연정, 정주호, 김창주, 김연희, 임백빈 : 갈화 약침이 알콜 중독 흰쥐의 치상회에서 신경세포 생성에 미치는 영향, 대한침구학회지, 18(6) : 206-214, 2001).Studies on browning significantly reduced ethanol concentrations in the blood, brain and liver of rats. Tectorigenin and kaikasaponin III isolated from browning were free radicals in subacute alcoholic rats. By inhibiting the production enzymes to restore liver damage caused by alcohol, and involved in the alcohol metabolism enzyme system affected the detoxification effect. Kakkalide and its metabolites were found to inhibit blood alcohol concentrations in mice (Hyeok Han: Kakalide and its metabolites inhibited blood alcohol levels and metabolic enzymes in mice) Partial Separation and Purification, Graduate School of Kyunghee University, 2002) (Niiho Y, Yamazaki T, Nakajima Y, Itoh H, Takeshita T, Kinjo J, Nohara T .: Pharmacological studies on puerariae flos.: I. The effects of pu-erariae flos on alcoholic metabolism and spontaneous movement in mice, Yakugaku Zasshi, 109 (6): 424-431, 1989), Gall needles produced more neurons in the dentate gyrus of alcoholic rats (Seo Jung-cheol, Kim Lee-hwa, Rose Hyun, Kim Yeon-jeong, Jung Ho-ho, Kim Chang-joo, Kim Yeon-hee, Lim Baek-bin: Korean Journal of Acupuncture and Moxibustion, 18 (6): 206-214, 2001).
또한, 본 발명의 주요 약물인 지구자는 갈매나무과(Rhamnaceae)식물인 헛개나무(Hovenia dulcis T.)의 육질이 있는 과실 꼭지가 달린 열매나 종자로 지갈제번(止渴除煩), 청열(淸熱), 해주독, 통리이변(通利二便)시키는 효능을 가지고 있어 해독을 푸는데 주로 이용되었다. 헛개나무의 추출물로부터 숙취해소를 시키는 C17H16O8의 호베노-둘리놀(hoveno-dulinol)을 분리하여 알코올과 함께 쥐에 투여한 결과 ADH와 ALDH의 효소활성이 증가하였고(홍유리, 김민희, 안철, 이현용, 김종대 : 헛개나무 추출물의 생리활성에 관한 연구, 강원대학교 농업과학연구소 논문집, 11 : 1-11, 2000), 헛개나무 추출물과 오리나무 추출물이 쥐와 사람의 체내 알코올 분해능을 증가시키며, 쥐에 간염을 유발한 후에 헛개나무 추출물을 첨가하였을 경우 간염 치료 효과가 있고, 헛개나무의 추출물이 알코올을 투여한 쥐의 혈중 알코올 농도를 저하시키는 효과가 있음이 보고되었다(안상욱, 김영길, 김민희, 이병익, 이상호, 권혁일, 황백, 이현용 : 헛개나무와 오리나무 추출물의 간 해독작용 및 체내 알콜 분해능 비교, 韓國藥用作物學會誌, 7(4) : 263-268, 1999). 지구자를 포함한 숙취해소용 음료로 개발된 건강음료를 각각 알코올 투여 30분 전과 후에 경구 섭취시키고 섭취 후 1시간, 5시간째 혈액 중 알코올 농도와 아세트알데히드 농도를 측정한 결과, 대조군에 비해 지구자를 포함한 건강음료가 알코올 농도를 48%, 아세트알데히드 농도를 36% 낮추었다(강성희, 김성문, 김진현 : 헛개열매 추출물의 산 가수분해에 의한 알코올 분해 효능 증대, 한국생물공학회지, 20(2) : 129-132, 2005). 지구자 물추출물이 에탄올 중독된 흰쥐의 학습능력에 미치는 영향을 실험하기 위하여 정상군(normal), 25%에탄올 투여군(control) 및 지구자 물 추출물과 에탄올을 함께 투여한 검액 투여군으로 나누어 10일간 각약물을 투여한 후 11일째 1일 3회 실험을 직선 수로 실험을 시행하고, 다음날부터 3일간 1일 3회씩 실험한 T-미로실험을 시행한 결과, 정상군은 직선 수로실험과 T-미로실험에서 학습에 의하여 목표점 도달 소요시간이 유의성 있게 단축되고, 대조군은 기억력 쇠퇴로 인하여 학습능력이 현저히 감소하나, 지구자의 물 추출물을 계속적으로 투여한 시료군의 경우 에탄올 중독으로 저하된 학습 능력에 유의성 있는 회복을 나타냈다(임종필, 최훈, 송정모 : 에탄올에 중독된 흰쥐의 학습능력에 미치는 지구자의 효과, 韓國藥用作物學會誌, 11(3) : 232-235, 2003). 헛개나무의 수피, 목부, 과경 추출물은 혈중 알코올 농도를 저하시켰으며, 과경의 메탄올추출물보다는 열수 추출물이 알코올 분해효소(alcohol dehydrogenase)의 활성을 높여 알코올을 분해하는 것으로 나타났다(임종필, 최훈, 송정모 : 에탄올에 중독된 흰쥐의 학습능력에 미치는 지구자의 효과, 韓國藥用作物學會誌, 11(3) : 232-235, 2003). 헛개 나무 추출물과 오리나무 추출물들이 쥐와 사람을 대상으로 실험한 결과 체내 알코올 분해능이 있는 것으로 나타났으며, 쥐 실험의 경우 헛개 나무가 32%의 알코올 분해능이 증진되었으며 오리나무는 13%정도로 나타났으며 혼합물인 경우 42%의 높은 것으로 나타났다. 또한 쥐와 사람에게 알코올과 같이 투여시 ADH와 ALDH효소 활성을 증진시킴으로써 알코올 분해 증진효과를 확인 할수 있었다(김영길, 이상호, 권혁일, 황백, 이현용, 안상욱, 김민회, 이병익 : 헛개나무와 오리나무 추출물의 간 해독작용 및 체내 알콜 분해능 비교, 韓國藥用作物學會誌, 7(4) : 263-268, 1999).In addition, the earth, the main drug of the present invention, is a fruit or seed with a fleshy fruit stalk of Rhovenaceae (Hovenia dulcis T.), a plant of Rhamnaceae. , Haejudok, Tongryui (通 利 二 便) has the efficacy of mainly used to solve the detoxification. When Hoveno-dulinol of C17H16O8 was removed from the extracts of the larvae and administered to rats with alcohol, the enzyme activities of ADH and ALDH were increased (Hong Yuri, Kim Min Hee, Ahn Cheol, Lee Hyun Yong) , Jong-Dae Kim: Studies on the Physiological Activity of the Extracts of the Barley Tree, Journal of Agricultural Sciences, Kangwon National University, 11: 1-11, 2000), The Barley Tree Extract and Alder Extract Increase the Alcohol Degradation in Rats and Humans It has been reported that the addition of the extract of the bark tree after inducing hepatitis has a therapeutic effect on the hepatitis, and the extract of the bark tree has the effect of lowering the blood alcohol concentration of the alcohol-administered rats (Sang Wook Ahn, Kim Young Gil, Kim Min Hee, Lee Byung Ik, Lee, Sang-Ho, Hyuk-Il Hwang, Baek-Hyun Lee, and Hyong-Yong Lee: Comparison of liver detoxification and alcohol degradability of bark and alder extract, 韓國 藥用 作物 學會 誌, 7 (4): 263-268, 1999). Healthy drinks developed as hangover-relieving beverages were taken orally 30 minutes before and after alcohol administration, and blood and acetaldehyde levels were measured at 1 and 5 hours after ingestion. Health drink lowered alcohol concentration by 48% and acetaldehyde concentration by 36% (Kang, Seong-hee, Kim, Sung-moon, Kim, Jin-hyun: Increased alcohol-degrading effect by acid hydrolysis of extracts of barberry, Korean Journal of Biotechnology and Bioengineering, 20 (2): 129- 132, 2005). To test the effect of the Earth's water extract on ethanol-addicted rats' learning ability, divided into two groups: normal, 25% ethanol-controlled group, and sample-administered group administered with earth-water extract and ethanol. After administering the drug, the experiment was conducted three times a day with a straight line and the T-maze experiment was performed three times a day for three days from the next day. The time required to reach the target point was significantly shortened by learning in the control group, and the control group significantly decreased the learning ability due to the decline of memory, but in the case of the sample group continuously administered the water extract of the earth, the learning ability was significantly decreased due to ethanol poisoning. Recovery (Lim Jong Pil, Choi Hoon, Song Jung Mo: Effect of Earthling on Learning Ability of Rats Addicted to Ethanol, 韓國 藥用 作物 學會 誌, 11 (3): 232-235, 2003). Bark, throat, and fruit extracts of the bark tree decreased blood alcohol concentration, and hot water extracts decomposed alcohol by increasing the activity of alcohol dehydrogenase (Lim Jong-Pil, Choi Hoon, Song Jung-Mo: Effect of Earthling on the Learning Ability of Ethanol-addicted Rats, 11 (3): 232-235, 2003). As a result of experiments in rats and alders extracts of rats and humans, it was found that there was alcohol degradation in the body. And 42% for the mixture. In addition, the effects of alcohol degradation could be confirmed by enhancing ADH and ALDH enzyme activity when administered to mice and humans (Kim Young-gil, Lee Sang-ho, Kwon Hyuk-il, Hwang-baek, Lee Hyun-yong, Ahn Sang-uk, Kim Min-hoe, Lee Byung-ik: Liver Detoxification and Alcohol Degradation in the Body, 韓國 藥用 作物 學會 誌, 7 (4): 263-268, 1999).
향부자는 방동사니과(Cyperaceae)에 속한 다년생 초본인 향부자(Cyperus ro-tundus L.)의 근경을 건조한 것으로 이기해울(理氣解鬱), 조경지통(調經止痛) 등의 효능이 있어 간기울체로 인한 흉협완복창통(胸脅脘腹脹痛), 월경부조 등을 치료한다. 향부자 추출물의 메스암페타민과 니코틴에 대한 의존, 우울증, 불안증에 대한 효과와 치료 약물로서 캐나비노이드 수용체와 시그마 수용체와의 연관성을 연관성을 보기위한 연구에서는 향부자추출물이 CB₁과 σ₁수용체 길항 또는 효현 효과를 통해 약물 중독과 우울증, 불안증에 대한 치료 효과를 가진 것으로 판단되었다(정민숙 : 메스암페타민과 니코틴 의존에 대한 향부자 추출물의 영향, 전북대학교 대학원, 2006).Hyangbuja is a dried root of the perennial herbaceous cyperus ro-tundus L. belonging to the Cyperaceae family. It is effective for self-sealing, landscaping pain, etc. Treats cramps and dysmenorrhea. In the study to investigate the effects of flavor extracts on methamphetamine and nicotine dependence, depression, and anxiety and the association between cannabinoid receptors and sigma receptors as therapeutic drugs, the extracts of perfume extracts were found to be effective through the effects of CB₁ and σ₁ receptor antagonism or agonistic effects. It was judged to have a therapeutic effect on drug addiction, depression and anxiety (Jung, Min Sook: Effect of Hyangbuja Extract on methamphetamine and nicotine dependence, Graduate School of Chonbuk National University, 2006).
위와 같은 단미연구를 살펴보면, 갈근, 갈화, 지구자, 향부자 등은 갈근해주탕이 알코올 의존 치료하는 중요한 작용을 하는 약물로 사료되며, 나머지 약물인 양강, 산사, 목과(모과), 백출, 지실, 진피, 봉출, 고삼 등의 효능과 기타 관련 연구에 대하여는 하기 표 1과 같다. Looking at the above simple rice research, brown root, brown hair, earth, and Hyangbuja are considered to be important drugs for the treatment of alcohol dependence by Galgeju-tang, and the remaining drugs such as Yanggang, hawthorn, tree (Chinese quince), baekrye, jirye, Efficacy and other related studies of the dermis, bleeding, and ginseng are shown in Table 1 below.
Study of free radical scavenging activity test of Chinese herbal medicine (compared with existing antioxidants)
조습(燥濕)
거풍(祛風)
살충(殺蟲)passion
Humidity
Geopung
Insecticide
카드뮴 독성에 의하여 손상된 NIH 3T3 섬유아세포의 재생효과 연구Inhibitory Effect on the Increase of C-fos Positive Peptides Increased by XO / HX
Regeneration Effect of NIH 3T3 Fibroblasts Damaged by Cadmium Toxicity
조습(燥濕)Selfishness,
Humidity
상기 기존 갈근해주탕은 갈화와 지구자를 포함하고 있지 않으며, 알코올 분해능을 밝힌 바 있으나 알코올 의존증의 유전적 요인에 대한 효과 연구는 지금까지 없는 실정이다. The existing Galgunju-tang does not contain gallium and tertiary, and has revealed alcohol degrading ability, but there is no research on the effects of genetic factors of alcohol dependence.
한편, 알코올을 좋아하는 정도가 높으면 시상하부의 POMC mRNA 발현 정도가 높고 알코올은 시상하부에서 베타-엔돌핀의 생성을 증가시키는 것으로 알려져 있다(Dennis D. Rasmussen, Brian M. Boldt, Charles W. Wilkinson, and Dennis R. Mitton : Opiomelanocortin Gene Expression And Implications For Dependence, Relapse, And Deprivation Effect ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH, 26(4) : 535-546, 2002). 베타 엔돌핀은 POMC의 PTP(posttranslational processing)에 의해 생성되는데, POMC는 ACTH, 베타-엔돌핀, α-,β-,γ-MSH의 생산에 필요한 전구물질로 뇌하수체와 시상하부에서 렙틴에 의해 발현된다. POMC는 각종 호르몬을 생산하여 GnRH의 분비에 영향을 주며, 생식 생리에서 중요한 역할을 담당한다. 베타 엔돌핀을 직접적으로 측정하는 것은 기술적으로 매우 어렵기 때문에, 알코올 의존을 연구하기 위하여는 β-EPLP (beta-endorphin -like peptide), POMC 일차 전사체나 POMC mRNA등을 측정한다. 측정 부위로는 뇌 시상하부의 궁상핵을 선택하여 측정하는데, 이는 시상하부에서 POMC를 합성하는 기전이 있기 때문이다.On the other hand, high alcohol preference is known to increase the expression level of hypothalamic POMC mRNA and alcohol increases the production of beta-endodolphin in the hypothalamus (Dennis D. Rasmussen, Brian M. Boldt, Charles W. Wilkinson, and Dennis R. Mitton: Opiomelanocortin Gene Expression And Implications For Dependence, Relapse, And Deprivation Effect ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH, 26 (4): 535-546, 2002). Beta endorphins are produced by the posttranslational processing (PTP) of POMC. POMC is a precursor required for the production of ACTH, beta-endorphin, α-, β-, γ-MSH and is expressed by leptin in the pituitary gland and hypothalamus. POMC produces various hormones that affect the secretion of GnRH and plays an important role in reproductive physiology. Since direct measurement of beta endorphins is technically very difficult, beta-endorphin-like peptide (PE-EPLP), POMC primary transcripts, and POMC mRNA are studied to study alcohol dependence. The measurement site is selected by measuring the arch nucleus of the hypothalamus of the brain, because there is a mechanism for synthesizing POMC in the hypothalamus.
또한, 알코올은 Endogenous Opioid system(EOPS)을 활성도를 증가시킨다고 알려졌는데 특히 알코올이 POMC를 증가시키는 것으로 알려져 있다. 알코올을 투여하였을 때, 알코올을 선호하지 않는 쥐(nP rats)에 비해 알코올을 선호하는 쥐(P rats)의 시상하부에서 POMC mRNA를 증가시켰으며, 높은 자발적 알코올 섭취를 하였으며(Krishnan-Sarin S, Wand GS, Li XW, Portoghese PS, Froehlich JC : Ef-fect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking, Pharmacol Biochem Behav, 59(3) : 627-635, 1998), 2개월 된 숫컷 C57BL/6와 DBA/2를 알코올 섭취 후 POMC mRNA 발현을 비교한 결과, C57BL/6형 생쥐가 DBA/2형보다 높게 나왔다(Jamensky NT, Gianoulakis C : Comparison of the Proopiomelanocortin and Proenkephalin Opioid Peptide Systems in Brain Regions of the Alcohol-Preferring C57BL/6 and Alcohol-Avoiding DBA/2 Mice, Alcohol, 18(2-3) : 177-187, 1999). 자발적인 알코올섭취가 C57BL/6와 DBA/2의 뇌의 베타-엔돌핀 시스템에 미치는 영향을 알아보기 위한 연구에서 C57BL/6가 DBA/2보다 훨씬 알코올 섭취량이 많았으며 자발적인 알코올 섭취는 시상하부에 있는 POMC mRNA를 증가시켰다. 그리고 베타 엔돌핀 유사 펩티드가 뚜렷히 증가하였다. 하지만 DBA/2에서는 베타-엔돌핀 시스템의 활성도를 변화시키지 못했다(De Waele J, Gianoulakis C : Enhanced activity of the brain β-endorphin system by free-choice ethanol drinking in C57BL/6 but not DBA/2 mice, European Journal of Pharmacology, 258(1-2) : 119-129, 1994). 높은 충동적 행동인 특징인 AA 랫트와 이에 비해 낮은 알코올 섭취를 가지는 ANA 랫트와 POMC mRNA 발현을 비교한 결과 AA 랫트가 보다 높은 경향을 나타냈다(Lindblom J, Wikberg JE, Bergstrom L : Alcohol-preferring AA rats s-how a derangement in their central melanocortin signalling system, Pharmacol Biochem Behav, 72(1-2) : 491-496, 2002). 또한 AA쥐가 ANA쥐에 비해 궁상핵에서 POMC mRNA의 양이 52%나 더 많으며, ANA쥐와 AA 쥐들을 대상으로 인시츄 하이브리다이제이션 방법을 통해 프로오피오멜라노코르틴, 프로엔케팔린, 프로디노르핀 mRNA를 비교한 결과, AA쥐들이 시상하부 궁형핵 안에 프로오피오멜라노코르틴 mRNA, 전두엽 피질 안의 프로엔케팔린 mRNA, 시상의 내측등쪽 피질 안에 프로디노르핀 mRNA가 의미있게 더 많음을 보여주었다(Marinelli PW, Kiianmaa K, Gianoulakis C : Opioid propeptide mRNA content and receptor density in the brains of AA and ANA rats, Life Scie-nces, 66(20) : 1915-1927, 2000). 임상 연구에서는 12명의 만성 알코올중독자와 12명의 비 알코올중독자에게 혈액을 채취하여 비교한 결과, 만성 알코올중독자에서 유의한 정도로 POMC mRNA 상승한 것이 나타났다(Rosenberger P, Muhlbauer E, Weissmuller T, Rommelspacher H, Sinha P, Wernecke KD, Finckh U, Rettig J, Kox WJ, Spies CD : Decreased proopiomelanocortin mRNA in lymphocytes of chronic alcoholics after intravenous human corticotropin releasing factor injection, Alcohol Clin Exp Res, 27(11) : 1693-1700, 2003). 또한 알코올중독자와 대조군의 POMC mRNA을 비교한 결과, 알코올중독자의 림프구에서 대조군보다 높았다(Winkler A, Schmidt LG, Rommelspacher H, Melzig MF : Quantification of proopiomelanocortin mRNA in peripheral lymphocytes of alcoholics, Alcohol, 15(1) : 43-50, 1998 ).In addition, alcohol is known to increase the activity of Endogenous Opioid system (EOPS), especially alcohol is known to increase POMC. When alcohol was administered, POMC mRNA was increased in the hypothalamus of alcohol-loving rats (P rats) compared to non-alcoholic rats (nP rats), and high spontaneous alcohol intake (Krishnan-Sarin S, Wand GS, Li XW, Portoghese PS, Froehlich JC: Ef-fect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking, Pharmacol Biochem Behav, 59 (3): 627-635, 1998), 2 months old Comparison of POMC mRNA expression in male C57BL / 6 and DBA / 2 after alcohol consumption showed that C57BL / 6 mice were higher than DBA / 2 type (Jamensky NT, Gianoulakis C: Comparison of the Proopiomelanocortin and Proenkephalin Opioid Peptide Systems in Brain Regions of the Alcohol-Preferring C57BL / 6 and Alcohol-Avoiding DBA / 2 Mice, Alcohol, 18 (2-3): 177-187, 1999). In a study to investigate the effects of spontaneous alcohol intake on the brain beta-endorphin system of C57BL / 6 and DBA / 2, C57BL / 6 consumed significantly more alcohol than DBA / 2, and spontaneous alcohol intake was observed in the hypothalamus mRNA was increased. And beta endorphin-like peptide was significantly increased. However, DBA / 2 did not alter the activity of the beta-endorphin system (De Waele J, Gianoulakis C: Enhanced activity of the brain β-endorphin system by free-choice ethanol drinking in C57BL / 6 but not DBA / 2 mice, European Journal of Pharmacology, 258 (1-2): 119-129, 1994). Compared with ANA rats with low alcohol consumption and POMC mRNA expression, AA rats, which are characterized by high impulsive behavior, showed higher tendency in AA rats (Lindblom J, Wikberg JE, Bergstrom L: Alcohol-preferring AA rats). s-how a derangement in their central melanocortin signaling system, Pharmacol Biochem Behav, 72 (1-2): 491-496, 2002). In addition, AA rats contained 52% higher amounts of POMC mRNA in the arch nucleus than ANA rats, and proopiomelanocortin, proenkephalin, and prodinor were administered to ANA rats and AA rats through in situ hybridization. Comparing the pin mRNA, AA mice showed significantly higher proopiomelanocortin mRNA in the hypothalamic arch nucleus, proenkephalin mRNA in the frontal cortex, and prodinorphine mRNA in the medial dorsal cortex (Marinelli). PW, Kiianmaa K, Gianoulakis C: Opioid propeptide mRNA content and receptor density in the brains of AA and ANA rats, Life Scie-nces, 66 (20): 1915-1927, 2000). In clinical studies, blood was collected from 12 chronic alcoholics and 12 nonalcoholics, indicating a significant increase in POMC mRNA in chronic alcoholics (Rosenberger P, Muhlbauer E, Weissmuller T, Rommelspacher H, Sinha P). , Wernecke KD, Finckh U, Rettig J, Kox WJ, Spies CD: Decreased proopiomelanocortin mRNA in lymphocytes of chronic alcoholics after intravenous human corticotropin releasing factor injection, Alcohol Clin Exp Res, 27 (11): 1693-1700, 2003). Compared with alcoholism and POMC mRNA of control group, it was higher than control group in alcoholic lymphocytes (Winkler A, Schmidt LG, Rommelspacher H, Melzig MF: Quantification of proopiomelanocortin mRNA in peripheral lymphocytes of alcoholics, Alcohol, 15 (1) : 43-50, 1998).
이에, 본 발명자들은 알코올 의존 동물모델인 C57BL/6 생쥐를 이용한 실험결과 갈화와 지구자를 포함한 혼합 생약재 추출물이 상기 동물 모델의 알코올 섭취 선호도를 감소시키고 더 나아가 베타 엔돌핀의 전구물질인 POMC mRNA 발현 정도를 유의하게 감소시키는 것을 확인함으로써 본 발명을 완성하였다. Therefore, the present inventors have used the alcohol-dependent animal model C57BL / 6 mice, and the mixed herbal extracts including browning and sapphire reduced the alcohol consumption preference of the animal model and further improved the expression level of POMC mRNA, a precursor of beta endorphin. The present invention has been completed by identifying significant reductions.
본 발명의 목적은 부작용이 없는 천연 성분인 갈화 및 지구자를 포함한 혼합 생약재 추출물을 이용한 알코올 의존증 예방 및 치료용 조성물을 제공하는 것이다.An object of the present invention to provide a composition for the prevention and treatment of alcohol dependence using a mixed herbal extracts, such as browning and earth, which are natural ingredients without side effects.
상기 목적을 달성하기 위하여, 본 발명은 물, 알코올 또는 이들의 혼합물을 용매로 하여 추출된 갈근, 갈화, 지구자, 향부자, 양강, 산사, 모과, 백출, 지실, 진피, 봉출 및 고삼을 포함하는 혼합 생약재 추출물을 제공한다. In order to achieve the above object, the present invention comprises a brown root, browning, earth, yangbuja, Yanggang, hawthorn, Chinese quince, baekrye, fruit room, dermis, sessile and ginseng extracted with water, alcohol or a mixture thereof as a solvent. Provides a blended herbal extract.
또한, 본 발명은 상기 혼합 생약재 추출물을 제조하는 방법을 제공한다. In addition, the present invention provides a method for producing the mixed herbal medicine extract.
또한, 본 발명은 상기 추출물을 유효성분으로 함유하는 알코올 의존증 예방 및 치료용 약학 조성물을 제공한다. The present invention also provides a pharmaceutical composition for preventing and treating alcohol dependence containing the extract as an active ingredient.
아울러, 본 발명은 상기 추출물을 유효성분으로 함유하는 알코올 의존증 예방 및 개선용 건강식품을 제공한다.In addition, the present invention provides a health food for preventing and improving alcohol dependence containing the extract as an active ingredient.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 물, 알코올 또는 이들의 혼합물을 용매로 하여 추출된 갈근, 갈화, 지구자, 향부자, 양강, 산사, 모과, 백출, 지실, 진피, 봉출 및 고삼을 포함하는 혼합 생약재 추출물을 제공한다. The present invention provides mixed herbal medicine extracts including brown root, brownish root, earthworm, saengbuja, Yanggang, hawthorn, Chinese quince, baekchul, fruiting, dermis, extract and ginseng extracted with water, alcohol or a mixture thereof as a solvent.
상기 혼합 생약재는 갈근, 갈화, 지구자, 향부자, 양강, 산사, 모과, 백출, 지실, 진피, 봉출 및 고삼을 각각 2~30 중량%을 포함하는 것이 바람직하며, 갈근, 갈화 및 지구자를 10~20 중량%, 양강, 산사, 향부자 및 지실을 5~12 중량%, 백출, 모과 및 고삼을 2~8 중량% 및 진피 및 봉출을 2~6 중량%을 포함하는 것이 더욱 바람직하나, 이에 제한되는 것은 아니다. The mixed herbal medicines preferably contain 2 to 30% by weight of each of the roots, brown roots, brown roots, earthworms, hyangbuja, Yanggang, hawthorn, Chinese quince, baekchul, fruiting, dermis, and extracts of ginseng. More preferably, 20% by weight, Yanggang, hawthorn, saengbuja and fruit fat, 5 to 12% by weight, baekchul, Chinese quince and red ginseng, 2 to 8% by weight and dermis and buds 2 to 6% by weight, but is not limited thereto. It is not.
상기 알코올은 C1 내지 C4 저급 알코올인 것이 바람직하며, 이에 제한되는 것은 아니며, 저급 알코올은 에탄올 또는 메탄올이 바람직하다. Preferably, the alcohol is a C 1 to C 4 lower alcohol, but is not limited thereto, and the lower alcohol is preferably ethanol or methanol.
또한, 본 발명은 In addition,
1) 갈근, 갈화, 지구자, 향부자, 양강, 산사, 목과, 백출, 지실, 진피, 봉출 및 고삼 각각 2~30 중량%를 포함하는 혼합 생약재를 물, 알코올 또는 이들의 혼합물을 이용하여 상온 또는 가열 진탕하여 추출액을 제조하는 단계;1) At room temperature using a mixture of herbal medicines containing 2-30% by weight of brown root, brown hair, earth, saengbuja, Yanggang, hawthorn, throat, white peach, dermis, dermis, extract and red ginseng, using water, alcohol or mixtures thereof. Preparing an extract by shaking with heat;
2) 단계 1의 추출액으로부터 고형분을 제거하고 농축하는 단계로 구성된 혼합 생약재 추출물을 제조하는 방법을 제공한다. 2) It provides a method for producing a mixed herbal medicine extract consisting of the step of removing solids from the extract of step 1 and concentrating.
본 발명의 혼합 생약재 추출물은 기존의 경희의료원 한방병원『경희한방처방집』의 갈근해주탕 원방에(경희대학교 한의과대학 부속한방병원 : 경희한방처방집, 경희의료원, 서울, p.533, 1997)에 갈화 및 지구자를 추가적으로 함유한 것으로, 갈근, 갈화, 지구자, 향부자, 양강, 산사, 목과, 백출, 지실, 진피, 봉출 및 고삼을 각각 2~30 중량% 포함하는 것을 특징으로 한다.The mixed herbal medicine extract of the present invention is galvanized in the original root of Geunjuju-tang (Kyung Hee Oriental Medicine Hospital, Kyung Hee Oriental Medicine Hospital, Kyung Hee Medical Center, Seoul, p.533, 1997). And additionally containing the earth, characterized in that it comprises 2-30% by weight of brown root, browning, earth, hyangbuja, Yanggang, hawthorn, neck, white baekrye, fruit room, dermis, and ginseng.
본 발명의 혼합 생약재 추출물의 항갈망 효과와 기전을 알아보고자 알코올 의존 동물 모델인 C57BL/6 생쥐를 이용하여 동물실험을 실시하였다. 본 연구의 대상으로 사용된 동물인 C57BL/6형 생쥐는 생체 활성이 높으며, 뇌수종과 눈 이상 발생율이 높고 탈모가 잘되어 종양세포 이식연구에 사용되고 알코올, 몰핀에 대하여 기호성이 높아 중독의 유전적 연구, 약물의 효능 연구 등에 많이 사용된다(Meliska CJ, Bartke A, McGlacken G, Jensen RA : Ethanol, nicotine, am-phetamine, and aspartame consumption and preferences in C57BL/6 and DBA/2 mice, Pharmacol Biochem Behav, 50(4) : 619-626, 1995). 특히, C57BL/6은 유사한 종인 C3H/HeJ에 비해 구강으로 자유롭게 섭취한 알코올, 니코틴 소비에서 월등히 높은 차이가 있는 것으로 알려졌으며(Li XC, Karadsheh MS, Jenkins PM, Stitzel JA : Genetic correlation bet-ween the free-choice oral consumption of nicotine and alcohol in C57BL/6JxC3H/HeJ F2 intercross mice, Behav Brain Res, 157(1) : 79-90, 2005), C57BL/6은 129P3/J 순종의 생쥐보다 전체적으로 알코올 섭취량과 알코올 선호도가 높았으며(Bachmanov AA, Reed DR, Li X, Li S, Beauchamp GK, Tordoff MG : Voluntary ethanol consumption by mice: genome-wide analysis of quantitative trait loci and their interactions in a C57BL/6ByJ x 129P3/J F2 intercross, Genome Res, 12(8) : 1257-1268, 2002), C57BL/6은 알코올 비선호적인 생쥐인 DBA/2에 비해 월등히 높은 알코올 섭취와 알코올 선호도를 보였다(Meliska CJ, Bartke A, McGlacken G, Jensen RA : Ethanol, nicotine, am-phetamine, and aspartame consumption and preferences in C57BL/6 and DBA/2 mice, Pharmacol Biochem Behav, 50(4) : 619-626, 1995). 이렇게, C57BL/6은 알코올의 자발적 섭취량과 알코올 선호도가 높아 알코올 의존의 치료 약물 연구에 많이 사용되는 동물모델이다(Unwin JW, Taberner PV : Voluntary ethanol consumption after ethanol and acetaldehyde treatment in alcohol-preferring C57BL mice, Psych-opharmacology (Berl), 78(4) : 361-364, 1982 ).To investigate the anti-craving effect and mechanism of the mixed herbal medicine extract of the present invention, an animal experiment was conducted using C57BL / 6 mice, which are alcohol-dependent animal models. C57BL / 6 mice, the animals used in this study, have high bioactivity, high incidence of hydrocephalus and eye abnormalities, and good hair loss for tumor cell transplantation, and high palatability for alcohol and morphine. (Meliska CJ, Bartke A, McGlacken G, Jensen RA: Ethanol, nicotine, am-phetamine, and aspartame consumption and preferences in C57BL / 6 and DBA / 2 mice, Pharmacol Biochem Behav, 50 (4): 619-626, 1995). In particular, C57BL / 6 was found to have a significantly higher difference in consumption of alcohol and nicotine freely consumed orally than similar species C3H / HeJ (Li XC, Karadsheh MS, Jenkins PM, Stitzel JA: Genetic correlation bet-ween the free-choice oral consumption of nicotine and alcohol in C57BL / 6JxC3H / HeJ F2 intercross mice, Behav Brain Res, 157 (1): 79-90, 2005). Alcohol preference (Bachmanov AA, Reed DR, Li X, Li S, Beauchamp GK, Tordoff MG: Voluntary ethanol consumption by mice: genome-wide analysis of quantitative trait loci and their interactions in a C57BL / 6ByJ x 129P3 / J F2 intercross, Genome Res, 12 (8): 1257-1268, 2002), and C57BL / 6 showed significantly higher alcohol intake and alcohol preference than DBA / 2, an alcohol-preferred mouse (Meliska CJ, Bartke A, McGlacken G). , Jensen RA: Ethanol, nicotine, am-phetamine, and aspartame consum ption and preferences in C57BL / 6 and DBA / 2 mice, Pharmacol Biochem Behav, 50 (4): 619-626, 1995). Thus, C57BL / 6 is an animal model that is widely used for the study of alcohol-dependent therapeutic drugs due to the spontaneous intake of alcohol and the preference for alcohol (Unwin JW, Taberner PV: Voluntary ethanol consumption after ethanol and acetaldehyde treatment in alcohol-preferring C57BL mice, Psych-opharmacology (Berl), 78 (4): 361-364, 1982).
또한, 본 발명에서는 행동학적으로도 알코올 의존화하기 위하여 변형된 유한 접근법(limited access procedure)을 이용하였다(Stromberg MF, Casale M, Volpicelli L, Volpicelli JR, O’BRIEN CP : A Comparison of the Effects of the Opioid Antagonists Naltrexone, Naltri-ndole, and β-Funaltrexamine on Ethanol Consumption in the Rat, Alcohol, 15(4) : 281-289, 1998). 즉, 3주령의 C57BL/6형 생쥐를 3주간 안정화시킨 후, 약물 투여를 10일간 하면서 2시간 동안 알코올을 제공하여 2시간 알코올 섭취량을 측정하고, 나머지 22시간 동안의 물 섭취량을 측정하였는데, 이런 유한접근법은 알코올을 24시간 제공하는 방법(24h two-bottle choice technique)에 비해, 알코올 소비에 있어 다양한 약리학적 물질들의 효과에 대한 연구에 적합하며, 짧은 반감기를 가진 약물 혹은 두개 강내 주입으로 약효 지속시간이 짧은 약물연구에 효과적이며, 알코올 섭취에 있어 다양한 행동학적, 유전학적 요소까지 측정할 수 있는 장점이 있어 알코올 의존 연구에 많이 적용된다(Le AD, Ko J, Chow S, Quan B : Alcohol consumption by C57BL/6, BALB/c, and DBA/2 mice in a limited access paradigm, Pharmacol Biochem Behav, 47(2) : 375-378, 1994). 본 발명에서는 알코올 의존화를 위해 유한 접근법 적용하였는데, C57BL/6형 생쥐는 의존화 기간 직후, 2시간 동안 10%알코올 섭취량은 3.3g/kg정도이었다. 이는 다른 연구에서 실시하였던 알코올 의존 동물의 알코올 섭취량을 비교하면 충분한 선호적 알코올 섭취를 한다고 볼 수 있다. In addition, in the present invention, a modified finite approach (limited access procedure) was used to be alcohol-dependently (Stromberg MF, Casale M, Volpicelli L, Volpicelli JR, O'BRIEN CP: A Comparison of the Effects of the Opioid Antagonists Naltrexone, Naltri-ndole, and β-Funaltrexamine on Ethanol Consumption in the Rat, Alcohol, 15 (4): 281-289, 1998). That is, three weeks old C57BL / 6 mice were stabilized for three weeks, and then two hours of alcohol intake was measured for two hours while the drug was administered for 10 days, and water intake was measured for the remaining 22 hours. The finite approach is suitable for the study of the effects of various pharmacological agents on alcohol consumption, compared to the 24h two-bottle choice technique, and sustained medicinal effects with short half-life drugs or intracranial infusion. It is effective for short-term drug research, and it can be applied to alcohol dependence research because it can measure various behavioral and genetic factors in alcohol consumption (Le AD, Ko J, Chow S, Quan B: Alcohol consumption by C57BL / 6, BALB / c, and DBA / 2 mice in a limited access paradigm, Pharmacol Biochem Behav, 47 (2): 375-378, 1994). In the present invention, a finite approach was applied for alcohol dependence. C57BL / 6 mice had a 10% alcohol intake of 3.3 g / kg for 2 hours immediately after the dependency period. This suggests that the alcohol consumption of alcohol-dependent animals compared with other studies is sufficient for alcohol consumption.
본 발명의 바람직한 실시예에서는 혼합 생약재 추출물의 알코올 의존에 작용하는 기전을 밝히기 위해 베타-엔돌핀의 전구물질인 POMC mRNA 발현 정도를 측정하 였다. 알코올 의존의 정확한 원인은 아직 밝혀지지 않았지만, 베타-엔돌핀의 영향이 큰 것으로 알려져 있다. 에탄올은 내인성 아편계 펩티드인 베타-엔돌핀을 증가시키고, 아편계 수용체(opioid receptors)의 결합처를 변화시켜 Endogenous Opioid system(EOPS)의 이상으로 강화효과(reinforcing effects)를 나타낸다고 알려져 있다(Blum K, Topel H : Opioid peptides and alcoholism: genetic deficiency and chemical management, Funct Neurol, 1(1) : 71-83, 1986; Topel H : Beta-endorphin genetics in the etiology of alcoholism, Alcohol, 5(2) : 159-165, 1988; Gianoulakis C : The effect of ethanol on the biosynthesis and regulationof opioid peptides, Experientia, 45(5) : 428-435, 1989). 알코올을 좋아하는 정도가 높으면 시상하부의 POMC mRNA 발현 정도가 높고 알코올은 시상하부에서 베타-엔돌핀의 생성을 증가시키는 것으로 알려져 있다(Dennis D. Rasmussen, Brian M. Boldt, Charles W. Wilkinson, and Dennis R. Mitton : Opiomelanocortin Gene Expression And Implications For Dependence, Relapse, And Deprivation Effect ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH, 26(4) : 535-546, 2002). 베타 엔돌핀은 POMC의 PTP(posttranslational processing)에 의해 생성되는데, POMC는 ACTH, 베타-엔돌핀, α-,β-,γ-MSH의 생산에 필요한 전구물질로 뇌하수체와 시상하부에서 렙틴에 의해 발현된다. POMC는 각종 호르몬을 생산하여 GnRH의 분비에 영향을 주며, 생식 생리에서 중요한 역할을 담당한다. 베타 엔돌핀을 직접적으로 측정하는 것은 기술적으로 매우 어렵기 때문에, 알코올 의존을 연구하기 위하여는 β-EPLP (beta-endorphin -like peptide), POMC 일차 전사체나 POMC mRNA등을 측정한다. 측정 부위로는 뇌 시상하부의 궁상핵을 선택하여 측정하는데, 이는 시상하부에서 POMC를 합성하는 기전이 있기 때문이다.In a preferred embodiment of the present invention, the expression of POMC mRNA, a precursor of beta-endorphin, was determined to elucidate the mechanism of action on alcohol dependence of the mixed herbal extracts. The exact cause of alcohol dependence is not yet known, but beta-endorphin is known to have a large effect. Ethanol is known to increase the endogenous opioid peptide beta-endorphin and to alter the binding sites of opioid receptors, resulting in reinforcing effects beyond the Endogenous Opioid system (EOPS) (Blum K, Topel H: Opioid peptides and alcoholism: genetic deficiency and chemical management, Funct Neurol, 1 (1): 71-83, 1986; Topel H: Beta-endorphin genetics in the etiology of alcoholism, Alcohol, 5 (2): 159- 165, 1988; Gianoulakis C: The effect of ethanol on the biosynthesis and regulation of opioid peptides, Experientia, 45 (5): 428-435, 1989). Higher liking of alcohol is known to increase the expression of POMC mRNA in the hypothalamus and alcohol is known to increase the production of beta-endorphins in the hypothalamus (Dennis D. Rasmussen, Brian M. Boldt, Charles W. Wilkinson, and Dennis R. Mitton: Opiomelanocortin Gene Expression And Implications For Dependence, Relapse, And Deprivation Effect ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH, 26 (4): 535-546, 2002). Beta endorphins are produced by the posttranslational processing (PTP) of POMC. POMC is a precursor required for the production of ACTH, beta-endorphin, α-, β-, γ-MSH and is expressed by leptin in the pituitary gland and hypothalamus. POMC produces various hormones that affect the secretion of GnRH and plays an important role in reproductive physiology. Since direct measurement of beta endorphins is technically very difficult, beta-endorphin-like peptide (PE-EPLP), POMC primary transcripts, and POMC mRNA are studied to study alcohol dependence. The measurement site is selected by measuring the arch nucleus of the hypothalamus of the brain, because there is a mechanism for synthesizing POMC in the hypothalamus.
본 발명의 혼합 생약재 추출물의 알코올 의존에 대한 치료 기전을 알아보기 위해 POMC mRNA를 측정한 결과, 갈근해주탕 1일 투여군에 비해 7일 투여군에서 유의성 있게 낮아졌다(도 1). 알코올은 Endogenous Opioid system(EOPS)을 활성도를 증가시킨다고 알려졌는데 특히 알코올이 POMC를 증가시키는 것으로 알려져 있다. 알코올을 투여하였을 때, 알코올을 선호하지 않는 쥐(nP rats)에 비해 알코올을 선호하는 쥐(P rats)의 시상하부에서 POMC mRNA를 증가시켰으며, 높은 자발적 알코올 섭취를 하였으며(Krishnan-Sarin S, Wand GS, Li XW, Portoghese PS, Froehlich JC : Ef-fect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking, Pharmacol Biochem Behav, 59(3) : 627-635, 1998), 2개월 된 숫컷 C57BL/6와 DBA/2를 알코올 섭취 후 POMC mRNA 발현을 비교한 결과, C57BL/6형 생쥐가 DBA/2형보다 높게 나왔다(Jamensky NT, Gianoulakis C : Comparison of the Proopiomelanocortin and Proenkephalin Opioid Peptide Systems in Brain Regions of the Alcohol-Preferring C57BL/6 and Alcohol-Avoiding DBA/2 Mice, Alcohol, 18(2-3) : 177-187, 1999). 자발적인 알코올섭취가 C57BL/6와 DBA/2의 뇌의 베타-엔돌핀 시스템에 미치는 영향을 알아보기 위한 연구에서 C57BL/6가 DBA/2보다 훨씬 알코올 섭취량이 많았으며 자발적인 알코올 섭취는 시상하부에 있는 POMC mRNA를 증가시켰다. 그리고 베타 엔돌핀 유사 펩티드가 뚜렷히 증가하였다. 하지만 DBA/2에서는 베타-엔돌핀 시스템의 활성도를 변화시키지 못했다(De Waele J, Gianoulakis C : Enhanced activity of the brain β-endorphin system by free-choice ethanol drinking in C57BL/6 but not DBA/2 mice, European Journal of Pharmacology, 258(1-2) : 119-129, 1994). 높은 충동적 행동인 특징인 AA 랫트와 이에 비해 낮은 알코올 섭취를 가지는 ANA 랫트와 POMC mRNA 발현을 비교한 결과 AA 랫트가 보다 높은 경향을 나타냈다(Lindblom J, Wikberg JE, Bergstrom L : Alcohol-preferring AA rats s-how a derangement in their central melanocortin signalling system, Pharmacol Biochem Behav, 72(1-2) : 491-496, 2002). 또한 AA쥐가 ANA쥐에 비해 궁상핵에서 POMC mRNA의 양이 52%나 더 많으며, ANA쥐와 AA 쥐들을 대상으로 인시츄 하이브리다이제이션 방법을 통해 프로오피오멜라노코르틴, 프로엔케팔린, 프로디노르핀 mRNA를 비교한 결과, AA쥐들이 시상하부 궁형핵 안에 프로오피오멜라노코르틴 mRNA, 전두엽 피질 안의 프로엔케팔린 mRNA, 시상의 내측등쪽 피질 안에 프로디노르핀 mRNA가 의미있게 더 많음을 보여주었다(Marinelli PW, Kiianmaa K, Gianoulakis C : Opioid propeptide mRNA content and receptor density in the brains of AA and ANA rats, Life Scie-nces, 66(20) : 1915-1927, 2000). 임상 연구에서는 12명의 만성 알코올중독자와 12명의 비 알코올중독자에게 혈액을 채취하여 비교한 결과, 만성 알코올중독자에서 유의한 정도로 POMC mRNA 상승한 것이 나타났다(Rosenberger P, Muhlbauer E, Weissmuller T, Rommelspacher H, Sinha P, Wernecke KD, Finckh U, Rettig J, Kox WJ, Spies CD : Decreased proopiomelanocortin mRNA in lymphocytes of chronic alcoholics after intravenous human corticotropin releasing factor injection, Alcohol Clin Exp Res, 27(11) : 1693-1700, 2003). 또한 알코올중독자와 대조군의 POMC mRNA을 비교한 결과, 알코올중독자의 림프구에서 대조군보다 높았다(Winkler A, Schmidt LG, Rommelspacher H, Melzig MF : Quantification of proopiomelanocortin mRNA in peripheral lymphocytes of alcoholics, Alcohol, 15(1) : 43-50, 1998 ).POMC mRNA was measured to determine the therapeutic mechanism for the alcohol dependence of the mixed herbal medicine extract of the present invention, it was significantly lower in the 7-day administration group compared to the 1 day administration group Galgunjutang (Fig. 1). Alcohol is known to increase the activity of the Endogenous Opioid System (EOPS), especially alcohol, which is known to increase POMC. When alcohol was administered, POMC mRNA was increased in the hypothalamus of alcohol-loving rats (P rats) compared to non-alcoholic rats (nP rats), and high spontaneous alcohol intake (Krishnan-Sarin S, Wand GS, Li XW, Portoghese PS, Froehlich JC: Ef-fect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking, Pharmacol Biochem Behav, 59 (3): 627-635, 1998), 2 months old Comparison of POMC mRNA expression in male C57BL / 6 and DBA / 2 after alcohol consumption showed that C57BL / 6 mice were higher than DBA / 2 type (Jamensky NT, Gianoulakis C: Comparison of the Proopiomelanocortin and Proenkephalin Opioid Peptide Systems in Brain Regions of the Alcohol-Preferring C57BL / 6 and Alcohol-Avoiding DBA / 2 Mice, Alcohol, 18 (2-3): 177-187, 1999). In a study to investigate the effects of spontaneous alcohol intake on the brain beta-endorphin system of C57BL / 6 and DBA / 2, C57BL / 6 consumed significantly more alcohol than DBA / 2, and spontaneous alcohol intake was observed in the hypothalamus mRNA was increased. And beta endorphin-like peptide was significantly increased. However, DBA / 2 did not alter the activity of the beta-endorphin system (De Waele J, Gianoulakis C: Enhanced activity of the brain β-endorphin system by free-choice ethanol drinking in C57BL / 6 but not DBA / 2 mice, European Journal of Pharmacology, 258 (1-2): 119-129, 1994). Compared with ANA rats with low alcohol consumption and POMC mRNA expression, AA rats, which are characterized by high impulsive behavior, showed higher tendency in AA rats (Lindblom J, Wikberg JE, Bergstrom L: Alcohol-preferring AA rats). s-how a derangement in their central melanocortin signaling system, Pharmacol Biochem Behav, 72 (1-2): 491-496, 2002). In addition, AA rats contained 52% higher amounts of POMC mRNA in the arch nucleus than ANA rats, and proopiomelanocortin, proenkephalin, and prodinor were administered to ANA rats and AA rats through in situ hybridization. Comparing the pin mRNA, AA mice showed significantly higher proopiomelanocortin mRNA in the hypothalamic arch nucleus, proenkephalin mRNA in the frontal cortex, and prodinorphine mRNA in the medial dorsal cortex (Marinelli). PW, Kiianmaa K, Gianoulakis C: Opioid propeptide mRNA content and receptor density in the brains of AA and ANA rats, Life Scie-nces, 66 (20): 1915-1927, 2000). In clinical studies, blood was collected from 12 chronic alcoholics and 12 nonalcoholics, indicating a significant increase in POMC mRNA in chronic alcoholics (Rosenberger P, Muhlbauer E, Weissmuller T, Rommelspacher H, Sinha P). , Wernecke KD, Finckh U, Rettig J, Kox WJ, Spies CD: Decreased proopiomelanocortin mRNA in lymphocytes of chronic alcoholics after intravenous human corticotropin releasing factor injection, Alcohol Clin Exp Res, 27 (11): 1693-1700, 2003). Compared with alcoholism and POMC mRNA of control group, it was higher than control group in alcoholic lymphocytes (Winkler A, Schmidt LG, Rommelspacher H, Melzig MF: Quantification of proopiomelanocortin mRNA in peripheral lymphocytes of alcoholics, Alcohol, 15 (1) : 43-50, 1998).
이를 종합해 볼 때, 갈근해주탕은 POMC mRNA 발현을 낮추어 알코올 선호도를 감소시켜, 알코올의 영향을 줄여 알코올의 섭취를 막는다고 해석할 수 있다. Taken together, Galgunju-tang can be interpreted to reduce the alcohol preference by lowering the expression of POMC mRNA, thereby reducing the effect of alcohol to prevent alcohol intake.
또한, 본 발명은 상기 혼합 생약재 추출물을 유효성분으로 함유하는 알코올 의존증 예방 및 치료용 약학 조성물을 제공한다. In addition, the present invention provides a pharmaceutical composition for preventing and treating alcohol dependence containing the mixed herbal medicine extract as an active ingredient.
본 발명의 약학 조성물은 상기 혼합 생약재에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 상기 조성물은 임상 투여 시에 경구 또는 비경구로 투여가 가능하며 일반적인 의약품 제제의 형태로 사용될 수 있다. 본 발명의 조성물은 각종의 투여 경로를 통하여 유효한 양으로 투여될 수 있다. 상기 용도는 약제학적으로 허용되는 담체를 함께 함유한다. 보다 구체적으로 약제학적으로 허용되는 담체로는 멸균용액, 정제, 코팅정 및 캡슐과 같은 공지된 제형들에 사용될 수 있는 표준의 약제학적 담체라면 어느 것이든 가능하다. 통상적으로 담체는 전분, 밀크, 당, 특정종류의 클레이, 젤라틴, 스테아린산, 탈크, 식물성 기름 또는 오일, 검, 글리콜류 등의 부형제 또는 기타 다른 공지의 부형제를 포 함할 수 있으며 또한 풍미제, 색소 첨가제 및 다른 성분들이 포함될 수 있다. 본 발명의 혼합 생약재 추출물을 유효성분으로 함유한 조성물을 투여하기 위한 제제는 통상적인 방법으로 경구, 정맥내, 근육내, 경피 투여의 방법에 의해 투여할 수 있지만, 이들 방법에만 한정되는 것은 아니다. 실제 임상투여시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제 및 캡슐제 등이 포함되며, 이러한 고형제제는 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스 (lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제 및 보존제가 포함될 수 있다. 또한, 본 발명의 조성물은 비경구로 투여할 수 있으며, 비경구 투여는 피하주사, 정맥주사 또는 근육내 주사에 의한다. 비경구 투여용 제형으로 제제화하기 위해서는 상기 생약조성물을 포함하여 안정제 또는 완충제와 함께 물에서 혼합하여 용액 또는 현탁액으로 제조하고 이를 앰플 또는 바이알의 단위 투여형으로 제제한다.The pharmaceutical composition of the present invention may further contain one or more active ingredients exhibiting the same or similar functions in addition to the mixed herbal medicine. The composition may be administered orally or parenterally during clinical administration and may be used in the form of a general pharmaceutical formulation. The compositions of the present invention can be administered in effective amounts through various routes of administration. The use together contains a pharmaceutically acceptable carrier. More specifically, pharmaceutically acceptable carriers can be any standard pharmaceutical carrier that can be used in known formulations such as sterile solutions, tablets, coated tablets and capsules. Typically, the carrier may contain excipients such as starch, milk, sugar, certain types of clays, gelatin, stearic acid, talc, vegetable oils or oils, gums, glycols, or other known excipients, and also flavors, pigment additives. And other ingredients. The formulation for administering the composition containing the mixed herbal extract of the present invention as an active ingredient may be administered by oral, intravenous, intramuscular, or transdermal administration in a conventional manner, but is not limited thereto. In actual clinical administration, it can be administered in a variety of oral and parenteral formulations, which are formulated using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants and the like that are commonly used. Solid form preparations for oral administration include tablets, pills, powders, granules and capsules, and the like form at least one excipient such as starch, calcium carbonate, sucrose or lactose. (lactose), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Oral liquid preparations include suspensions, liquid solutions, emulsions, syrups, and the like, and may include various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents, water and liquid paraffin. In addition, the compositions of the present invention can be administered parenterally, and parenteral administration is by subcutaneous injection, intravenous injection or intramuscular injection. In order to formulate into a parenteral formulation, it is prepared in solution or suspension by mixing in water with a stabilizer or buffer, including the herbal composition, and formulated in a unit dosage form of ampoules or vials.
본 발명의 조성물의 투여량은 체내에서 활성성분의 흡수도, 불활성화율, 배설속도, 환자의 연령, 성별 및 상태, 치료할 질병의 중증 정도에 따라 적절히 선택 되나, 일반적으로 1일에 1회 내지 3회로 나누어 투여할 수 있다. 본 발명의 조성물에서 상기 혼합 생약재 추출물을 유효성분으로 함유하는 경우, 그 유효용량은 100~1,000 mg/kg/day이고, 바람직하기로는 100~500 mg/kg/day 이다. 상기 제제의 정확한 양, 투여경로 및 횟수는 제제의 특성, 투여대상의 체중 및 상태, 그리고 사용하고자 하는 특정 유도체의 특성에 따라 용이하게 결정할 수 있다.The dosage of the composition of the present invention is appropriately selected depending on the absorbency, inactivation rate, rate of excretion, the age, sex and condition of the patient, and the severity of the disease to be treated in the body, but generally once to three times a day. It can be administered in divided doses. When the mixed herbal medicine extract in the composition of the present invention as an active ingredient, the effective dose is 100 ~ 1,000 mg / kg / day, preferably 100 ~ 500 mg / kg / day. The exact amount, route of administration, and frequency of the agent can be readily determined according to the nature of the agent, the weight and condition of the subject to be administered, and the nature of the particular derivative to be used.
본 발명의 조성물은 알코올 의존증의 예방 및 치료를 위하여 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The compositions of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention and treatment of alcohol dependence.
또한, 본 발명은 상기 혼합 생약재 추출물을 유효성분으로 함유하는 알코올 의존증 예방 및 개선용 건강식품을 제공한다.The present invention also provides a health food for preventing and improving alcohol dependence containing the mixed herbal medicine extract as an active ingredient.
본 발명의 혼합 생약재 추출물을 식품으로 사용할 경우, 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용되고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 본 발명의 혼합 추출물을 식품 또는 음료의 제조 시에 원료에 대하여 0.1 내지 50 중량%, 바람직하게는 1 내지 10 중량%의 양으로 첨가될 수 있다. 본 발명의 혼합 추출물의 유효용량은 상기 약학적 조성물의 유효용량에 준해서 사용할 수 있으나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 범위 이하일 수 있으며, 유효성분은 안전성 면에서 아무런 문제가 없기 때문에 상기 범위 이상 의 양으로도 사용될 수 있음은 확실하다.When the mixed herbal medicine extract of the present invention is used as a food, it may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method. The blending amount of the active ingredient can be suitably determined according to the purpose of its use (prevention, health or therapeutic treatment). In general, the mixed extract of the present invention may be added in an amount of 0.1 to 50% by weight, preferably 1 to 10% by weight based on the raw materials in the manufacture of food or beverage. The effective dose of the mixed extract of the present invention may be used in accordance with the effective dose of the pharmaceutical composition, but may be less than the above range in the case of long-term intake for the purpose of health and hygiene or for health control. It is evident that the component can be used in an amount above the range because there is no problem in terms of safety.
상기 식품의 종류에는 특별한 제한은 없다. 상기 혼합 추출물을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등을 들 수 있다.There is no particular limitation on the kind of food. Examples of the food to which the mixed extract may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, teas, and drinks. Alcoholic beverages and vitamin complexes.
상기에서 살펴본 바와 같이, 본 발명의 혼합 생약재 추출물을 포함하는 조성물은 자발적 알코올 섭취와 관련된 POMC mRNA의 발현을 감소시켜 알코올의 섭취를 막음으로써 알코올 의존증의 예방 및 치료에 유용하게 이용될 수 있다. As described above, the composition comprising the mixed herbal medicine extract of the present invention can be usefully used for the prevention and treatment of alcohol dependence by preventing the intake of alcohol by reducing the expression of POMC mRNA associated with spontaneous alcohol intake.
이하, 본 발명을 실시예 및 시험예에 의해 상세히 설명한다. 단, 하기 실시예 및 시험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용을 한정하지는 않는다.Hereinafter, the present invention will be described in detail by Examples and Test Examples. However, the following Examples and Test Examples are only illustrative of the present invention, and do not limit the content of the present invention.
<< 실시예Example 1> 혼합 1> mix 생약재Herbal medicine 추출물(이하, ' Extract (" 갈근Rooting 해주탕Haejutang '이라 칭함)의 제조Manufacturing)
경희의료원 한방병원『경희한방처방집』의 갈근해주탕 원방에(경희대학교 한의과대학 부속한방병원 : 경희한방처방집, 경희의료원, 서울, p.533, 1997) 지구자 12 g을 첨가하여 새롭게 구성한 처방으로, 1첩(85 g)단위로 10첩(850 g)을 전탕 후 냉동 건조하여 분말상태로 만들어 사용하였다. 갈근해주탕의 구성내용 및 분량은 표 2와 같다.It is a newly formulated prescription made by adding 12 g of earth's earth to Geun-ju Hae-tang of Kyunghee Medical Center Oriental Medicine Hospital Kyunghee Medical Center (Kyung Hee Oriental Medicine Hospital, Kyung Hee Oriental Medicine Hospital, Kyung Hee Medical Center, Seoul, p.533, 1997). , 10 pouches (850 g) were applied in a single pouch (85 g) unit, and then frozen and dried in a powder state. The content and quantity of Galgeju-tang are shown in Table 2.
약재 1첩당 물 300cc의 비율로 혼합하여 환류 냉각장치에서 3시간 동안 가열 후 1차 전탕액을 얻었다. 이 전탕액을 다시 회전식 진공플라스크에 넣고 감압 농축시켜 2차 원액을 얻었다. 2차 원액은 다시 동결건조과정을 거쳐 고체 형태의 추출물로 만들어졌다. 이를 분쇄기로 분쇄하여 분말상태 103.8g을 얻었다.The mixture was mixed at a rate of 300 cc of water per medicinal herb, and then heated for 3 hours in a reflux condenser to obtain a primary warm water. This warm water was put into a rotary vacuum flask again and concentrated under reduced pressure to obtain a secondary stock solution. The second stock solution was again lyophilized into a solid extract. This was pulverized with a grinder to obtain 103.8 g of powder.
이를 일반 성인(60kg)의 kg당 1일 섭취량으로 환산하면 345 mg/kg이며, 다시 생쥐 한 마리당 섭취량으로 계산하면 8.6 mg/생쥐(체중 25g기준)이다. This translates into a daily intake of 345 mg / kg per kg of an adult (60 kg) and 8.6 mg / mouse (based on a 25g body weight).
<실시예 2> 갈근해주탕 low dose군(GHT-L)<Example 2> low dose group (GHT-L)
갈근해주탕 low dose군(GHT-L)의 섭취용량은 상기 실시예 1에서 제조된 갈근해주탕을 생쥐의 1일 섭취량보다 2배 높은 농도로 투여하여 1일 17.2 mg/생쥐(688 mg/kg)을 투여하였다. Intake dose of the low dose group (GHT-L) Galgeju-tang is administered 17.2 mg / mouse (688 mg / kg) per day by administering the galgejuju-tang prepared in Example 1 at a concentration twice higher than the daily intake of the mouse ) Was administered.
<실시예 3> 갈근해주탕 high dose군(GHT-H)<Example 3> Brown root haejutang high dose group (GHT-H)
갈근해주탕 high dose군(GHT-H)은 생쥐의 1일 섭취량보다 10배 높은 농도로 투여하여 1일 86.0 mg/생쥐(3450 mg/kg)을 투여하였다. The high dose group (GHT-H) of Galgunju-tang was administered at a concentration 10 times higher than the daily intake of mice to administer 86.0 mg / mouse (3450 mg / kg) per day.
<비교예 1> 갈화와 지구자가 없는 갈근해주탕<Comparative Example 1> Brown root soup without gallium and earth
기존의 갈화와 지구자가 포함되지 않은 갈근해주탕을 비교예 1로 하였다. 비교예 1의 갈근해주탕은 갈화와 지구자를 제외하고 실시예 1과 동일하게 제조하였다. 비교예 1의 갈근해주탕은 상기 GHT-H군과 동일하게 생쥐의 1일 섭취량보다 10배 높은 농도로 투여하여 1일 86.0mg/mouse(3450mg/kg)을 투여하였다. Comparative example 1 was used as the root galgejutang which does not contain the existing browning and earth globe. Brown root haejutang of Comparative Example 1 was prepared in the same manner as in Example 1 except for the grinding and earth. Galgeunjutang of Comparative Example 1 was administered in a concentration 10 times higher than the daily intake of the mice in the same manner as the GHT-H group was administered 86.0mg / mouse (3450mg / kg) per day.
<실험예 1> 갈근해주탕의 알코올 의존증 치료효과Experimental Example 1 Treatment Effect of Galgejujutang Alcohol Dependence
본 발명의 갈근해주탕의 알코올 의존증의 치료효과를 알아보기 위하여, 하기와 같은 실험을 수행하였다.In order to determine the therapeutic effect of the alcohol dependence of Galgejujutang of the present invention, the following experiment was performed.
1. 실험동물1. Experimental Animal
실험 대상으로 3주령의 C57BL/6형 수컷 생쥐(효창 science, 대구)를 사용하였다. C57BL/6형 수컷 생쥐는 도착일로부터 5일 동안(실험 5일째까지) 한 우리당 5마리씩 사육하면서 실험환경에 적응시켰다. 이때 물과 생쥐용 배합사료(삼양유지사료주식 회사, 서울)는 24시간 동안 자유로이 섭취하도록 하였다.Three-week old C57BL / 6 male mice (Hyochang Science, Cod) were used as the test subjects. C57BL / 6 male mice were acclimated to the experimental environment by raising 5 animals per cage for 5 days (up to 5 days of the experiment) from the arrival date. Water and mouse compound feed (Samyang Oil Feed Co., Ltd., Seoul) was freely ingested for 24 hours.
이후 대상 생쥐의 행동학적 알코올 의존화를 위하여 변형된 유한 접근법(limited access procedure)을 이용하였다. 즉, 대상 생쥐를 한 우리당 한 마리씩 사육하면서 일주일 동안(실험 12일째까지)은 물 대신에 10%(v/v) 알코올(Sigma St, Louis, MO, USA)만을 사료와 함께 24시간 동안 제공함으로써 알코올 섭취를 강요하였다. 이후 3주 동안(실험 33일째까지)에는 매일 오후 2시부터 4시사이의 2시간 동안은 물 제공 없이 10%(v/v) 알코올만을 제공함으로써 이때에만 알코올 섭취를 할 수 있다는 것을 학습시켰다. 알코올이 제공되지 않는 나머지 22시간에는 물을 제공하였다. 사료는 모두 24시간 제공하였다. 명암은 06시부터 18시까지 12시간 간격으로 조절하였다.A modified finite approach was then used for behavioral alcohol dependence of the subject mice. That is, by raising one mouse per cage, for a week (up to the 12th day of the experiment), only 10% (v / v) alcohol (Sigma St, Louis, MO, USA) was provided for 24 hours with food instead of water. Alcohol consumption was forced. During the next three weeks (up to the 33rd day of the experiment), only 10% (v / v) alcohol was provided for 2 hours between 2 pm and 4 pm daily, so that only alcohol intake was learned. The remaining 22 hours without alcohol provided water. All feeds were provided 24 hours. Contrast was adjusted every 12 hours from 06 to 18:00.
약물 투여는 실험 38일째부터 47일째까지 10일간 시행하며, 이를 위해 약물 투여 첫날인 실험 38일째 오전에 생쥐를 무작위로 매개체군(vehicle)군은 0.1ml의 물을 투여하였으며, 갈근해주탕 추출물 투여군은 low dose 투여군(688 mg/kg, 실시예2)과 high dose 투여군(3.450 g/kg, 실시예3)으로 나누어 처리하였다. 일회 투여량은 처리군에 관계없이 모두 0.1 ml로 경구 투여하였으며, 각 투여군은 농도를 달리하였다. 약물 투여는 알코올 제공 시작 시간 2시간 전인 오전 12시에 시작하였다. 오후 2시부터 4시 사이의 2시간 동안 물 제공 없이 10%(v/v) 알코올을 제공하였다. 알코올이 제공되지 않는 22시간은 물을 제공하였으며, 사료는 24시간 모두 제공하였다. Drug administration was conducted for 10 days from the 38th day to the 47th day of the experiment. To this end, the mice were randomly administered 0.1 ml of water in the morning of the 38th day of the experiment, the first day of the drug administration. Was divided into a low dose administration group (688 mg / kg, Example 2) and a high dose administration group (3.450 g / kg, Example 3). All doses were orally administered at 0.1 ml irrespective of treatment groups, and each dose group was varied in concentration. Drug administration began at 12 am, two hours before the start of alcohol delivery. 10% (v / v) alcohol was provided without water provision for 2 hours between 2 pm and 4 pm. Twenty-two hours without alcohol were given water and feed was provided for all 24 hours.
2. POMC mRNA 발현 측정 2. Measurement of POMC mRNA Expression
실험대상으로 도착일로부터 5일 동안 한 우리당 5마리씩 사육하면서 실험환경에 적응시킨 C57/BL6형 수컷 생쥐(효창 science, 대구)를 사용하였다. 약물 투여는 약물 처리결과 일부 유의성이 나타난 갈근해주탕 high dose투여군(GHT-H)과 매개체군 및 갈화와 지구자를 포함하지 않은 기존의 갈근해주탕을 비교군으로 하였다. 투여량은 매개체군은 0.1 ml의 물을 투여하였으며, 갈근해주탕 추출물 처리군은 high dose 처리군인 3.45 g/kg투여군으로 나누어 처리하였으며, 비교군은 기존의 갈근해주탕을 3.45 g/kg 투여하였다. 일회 투여량은 투여군에 관계없이 모두 0.1 ml로 경구투여하였다. 약물 투여는 알코올 제공 시작 시간 2시간 전인 오전 12시에 투여하였다. 각 투여군은 궁상핵(arcuate nucleus)에서 POMC 유전자의 발현 정도를 측정하기 위하여 매개체군과 갈근해주탕 high dose 투여군으로 구분하여 투여 1일과 투여 7일째(각 그룹 9마리)에 마취 후 뇌를 적출하여 뇌중 시상하부의 궁상핵를 절취하여 실험의 재료로 사용하였다.C57 / BL6 male mice (Hyochang science, Daegu) adapted to the experimental environment were used as 5 subjects per cage for 5 days from the arrival date. The drug administration was compared with the high dose administration group (GHT-H), the mediator group, and the existing Galgeju-tang, which did not contain gallium and tertiary, which showed some significance as a result of drug treatment. The dosage was 0.1 ml of water in the mediator group, and the group treated with Galgeju-tang extract was divided into 3.45 g / kg administration group, which was a high dose treatment group, and the comparison group was administered 3.45 g / kg of the existing Galgejuju-tang. . All doses were orally administered at 0.1 ml regardless of the administration group. Drug administration was administered at 12 am, two hours before the start of alcohol delivery. In order to measure the expression level of POMC gene in the arcuate nucleus, each group was divided into mediator group and Galgeunju-tang high-dose group. The cervical nucleus of the hypothalamus of the brain was excised and used as a material for the experiment.
뇌 시상하부의 궁상핵을 절취한 직후 RNA를 분리하였다. RNA의 분리는 절취한 조직에 트리졸 용액을 700 ㎕ 넣은 다음 곱게 마쇄하였다. 이어서 클로로포름 용액을 200 ㎕넣은 후 12,000 rpm에서 원심 분리하여 상등액을 새 튜브에 넣고 이소프로필 알코올 200 ㎕를 넣은 후 냉동실에서 밤새 정치한 다음 12,000 rpm에서 원심 분리 후 상등액을 제거하였다. 여기에 75% 에탄올 700 ㎕를 넣고 원심 분리하였다. 원심 분리 후 상등액을 제거하고 튜브를 완전히 건조시킨 다음 DEPC 용액을 10-20 ㎕ 첨가하여 RNA를 추출하였다. 그리고 추출한 RNA는 스펙트로미터를 이용하여 정량하여 RT-PCR에 사용하였다.RNA was isolated immediately after cutting the arch nucleus of the hypothalamus of the brain. The RNA was separated into 700 μl of Trizol solution in the cut tissue and then finely ground. Subsequently, 200 µl of chloroform solution was added thereto, followed by centrifugation at 12,000 rpm, the supernatant was added to a new tube, 200 µl of isopropyl alcohol was added, and the mixture was allowed to stand overnight in a freezer, and then the supernatant was removed after centrifugation at 12,000 rpm. 700 μl of 75% ethanol was added thereto and centrifuged. After centrifugation, the supernatant was removed, the tube was completely dried, and RNA was extracted by adding 10-20 μl of DEPC solution. The extracted RNA was quantified using a spectrometer and used for RT-PCR.
POMC에 발현과 관련한 프라이머는 단편의 크기가 436 bp되게 하여 정방향 프라이머(서열번호 1: 5'-GAT TCT GCT ACA GTC GCT C-3')과 역방향 프라이머(서열번호 2: 5‘-GAA CTC TAG GGG AAA GGC-3')로 BIONICS사에 제작 의뢰하여 사용하였다. RT-PCR은 RT-PCR kit(Promega Co. USA)를 이용하여 RNase-free water 11 ㎕, AMV/Tfl 5ㅧ반응 완충액 4 ㎕, dNTP 혼합액 2 ㎕, 정방향과 역방향 프라이머를 각각 1 ㎕, 25 mM MgSO4 0.8 ㎕, AMV 역전사효소 0.4 ㎕, Tfl DNA 중합효소 0.4 ㎕ 첨가 후 주형 RNA 1 ㎕를 혼합한 다음, 45℃에서 45분간 역전사시켜 1차 가닥 cDNA를 합성하였다. 그리고 94℃에서 2분간 예열한 후 94℃에서 30초간 변성화반응(denaturation), 50℃에서 1분간 프라이머 결합 반응(annealing), 72℃에서 1분간 연장반응 과정을 40회 반복하고 최종적으로 72℃에서 7분간 반응하여 2차 가닥 cDNA를 합성하는 RT-PCR을 실시하였다. The primers related to expression in the POMC were 436 bp in size to the forward primers (SEQ ID NO: 1: 5'-GAT TCT GCT ACA GTC GCT C-3 ') and reverse primers (SEQ ID NO: 2: 5'-GAA CTC TAG). GGG AAA GGC-3 ') was used by BIONICS. RT-PCR using RT-PCR kit (Promega Co. USA), 11 μl RNase-free water, 4 μl AMV / Tfl 5fl reaction buffer, 2 μl dNTP mixture, 1 μl forward and reverse primer, 25 mM After addition of 0.8 μl of MgSO 4 , 0.4 μl of AMV reverse transcriptase, and 0.4 μl of Tfl DNA polymerase, 1 μl of template RNA was mixed, followed by reverse transcription at 45 ° C. for 45 minutes to synthesize primary strand cDNA. After preheating at 94 ° C. for 2 minutes, denaturation at 94 ° C. for 30 seconds, primer binding at 50 ° C. for 1 minute, and extension reaction at 40 ° C. for 1 minute were repeated 40 times and finally 72 ° C. After reacting for 7 minutes at RT-PCR to synthesize a second strand cDNA.
PCR 반응이 완료되면 2.0% 아가로오즈 젤에 전기 영동하여 RNA 밴드의 증폭유무를 확인하였으며, 증폭된 RNA 밴드는 각 밴드의 양을 밀도계로 측정하여 POMC mRNA의 발현 정도를 측정하였다. POMC mRNA의 측정 결과는 각 군의 평균 비교분석으로 독립 t-검증을 사용하여 검정하였다. Upon completion of the PCR reaction, electrophoresis was performed on 2.0% agarose gel to confirm the amplification of RNA bands. The amplified RNA bands were measured by measuring the amount of each band with a density meter to measure the expression of POMC mRNA. The measurement result of POMC mRNA was tested using an independent t-test as an average comparative analysis of each group.
갈근해주탕이 시상하부 POMC mRNA 발현에 미치는 영향을 알아보고자, 투여 후 1일째, 7일째 갈근해주탕 high dose군, 매개체군 및 비교군의 POMC mRNA 발현을 측정하여 세 군간 평균을 비교하였다. 그 결과, 1일째와 7일째 매개체군과 비교군 사이에서는 평균의 유의한 차이가 없었으나, 1일째와 7일째 갈근해주탕 high dose군 사이에서 평균의 유의한 차이가 있었다(p=0.043)(도 1).To evaluate the effect of galgejuju-tang on hypothalamic POMC mRNA expression, the mean values of the three groups were compared by measuring the POMC mRNA expression in the high dose group, mediator group and comparison group on day 1 and 7 after administration. As a result, there was no significant difference in the mean between the median group and the comparison group on the 1st and 7th day, but there was a significant difference between the high dose group of the galgeunjutang on the 1st and 7th day (p = 0.043) ( 1).
알코올은 Endogenous Opioid system(EOPS)을 활성도를 증가시킨다고 알려졌는데 특히 알코올이 POMC를 증가시키는 것으로 알려져 있다. 알코올을 투여하였을 때, 알코올을 선호하지 않는 쥐(nP rats)에 비해 알코올을 선호하는 쥐(P rats)의 시상하부에서 POMC mRNA를 증가시켰으며, 높은 자발적 알코올 섭취를 하였으며(Krishnan-Sarin S, Wand GS, Li XW, Portoghese PS, Froehlich JC : Ef-fect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking, Pharmacol Biochem Behav, 59(3) : 627-635, 1998), 2개월 된 숫컷 C57BL/6와 DBA/2를 알코올 섭취 후 POMC mRNA 발현을 비교한 결과, C57BL/6형 생쥐가 DBA/2형보다 높게 나왔다(Jamensky NT, Gianoulakis C : Comparison of the Proopiomelanocortin and Proenkephalin Opioid Peptide Systems in Brain Regions of the Alcohol-Preferring C57BL/6 and Alcohol-Avoiding DBA/2 Mice, Alcohol, 18(2-3) : 177-187, 1999). 자발적인 알코올 섭취가 C57BL/6와 DBA/2의 뇌의 베타 엔돌핀 시스템에 미치는 영향을 알아보기 위한 연구에서 C57BL/6가 DBA/2보다 훨씬 알코올 섭취량이 많았으며 자발적인 알코올 섭취는 시상하부에 있는 POMC mRNA를 증가시켰다. 그리고 베타 엔돌핀 유사 펩티드가 뚜렷히 증가하였다. 하지만 DBA/2에서는 베타-엔돌핀 시스템의 활성도를 변화시키지 못했다(De Waele J, Gianoulakis C : Enhanced activity of the brain β-endorphin system by free-choice ethanol drinking in C57BL/6 but not DBA/2 mice, European Journal of Pharmacology, 258(1-2) : 119-129, 1994). 높은 충동적 행동인 특징인 AA 랫트와 이에 비해 낮은 알코올 섭취를 가지는 ANA 랫트와 POMC mRNA 발현을 비교한 결과 AA 랫트가 보다 높은 경향을 나타냈다(Lindblom J, Wikberg JE, Bergstrom L : Alcohol-preferring AA rats s-how a derangement in their central melanocortin signalling system, Pharmacol Biochem Behav, 72(1-2) : 491-496, 2002). 또한 AA쥐가 ANA쥐에 비해 궁상핵에서 POMC mRNA의 양이 52%나 더 많으며, ANA쥐와 AA 쥐들을 대상으로 인시츄 하이브리다이제이션 방법을 통해 프로오피오멜라노코르틴, 프로엔케팔린, 프로디노르핀 mRNA를 비교한 결과, AA쥐들이 시상하부 궁형핵 안에 프로오피오멜라노코르틴 mRNA, 전두엽 피질 안의 프로엔케팔린 mRNA, 시상의 내측등쪽 피질 안에 프로디노르핀 mRNA가 의미있게 더 많음을 보여주었다(Marinelli PW, Kiianmaa K, Gianoulakis C : Opioid propeptide mRNA content and receptor density in the brains of AA and ANA rats, Life Scie-nces, 66(20) : 1915-1927, 2000). 임상 연구에서는 12명의 만성 알코올중독자와 12명의 비 알코올중독자에게 혈액을 채취하여 비교한 결과, 만성 알코올중독자에서 유의한 정도로 POMC mRNA 상승한 것이 나타났다(Rosenberger P, Muhlbauer E, Weissmuller T, Rommelspacher H, Sinha P, Wernecke KD, Finckh U, Rettig J, Kox WJ, Spies CD : Decreased proopiomelanocortin mRNA in lymphocytes of chronic alcoholics after intravenous human corticotropin releasing factor injection, Alcohol Clin Exp Res, 27(11) : 1693-1700, 2003). 또한 알코올중독자와 대조군의 POMC mRNA을 비교한 결과, 알코올중독자의 림프구에서 대조군보다 높았다(Winkler A, Schmidt LG, Rommelspacher H, Melzig MF : Quantification of proopiomelanocortin mRNA in peripheral lymphocytes of alcoholics, Alcohol, 15(1) : 43-50, 1998 ).Alcohol is known to increase the activity of the Endogenous Opioid System (EOPS), especially alcohol, which is known to increase POMC. When alcohol was administered, POMC mRNA was increased in the hypothalamus of alcohol-loving rats (P rats) compared to non-alcoholic rats (nP rats), and high spontaneous alcohol intake (Krishnan-Sarin S, Wand GS, Li XW, Portoghese PS, Froehlich JC: Ef-fect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking, Pharmacol Biochem Behav, 59 (3): 627-635, 1998), 2 months old Comparison of POMC mRNA expression in male C57BL / 6 and DBA / 2 after alcohol consumption showed that C57BL / 6 mice were higher than DBA / 2 type (Jamensky NT, Gianoulakis C: Comparison of the Proopiomelanocortin and Proenkephalin Opioid Peptide Systems in Brain Regions of the Alcohol-Preferring C57BL / 6 and Alcohol-Avoiding DBA / 2 Mice, Alcohol, 18 (2-3): 177-187, 1999). In a study to investigate the effects of spontaneous alcohol intake on the brain beta endorphin system of C57BL / 6 and DBA / 2, C57BL / 6 was significantly more alcoholic than DBA / 2, and spontaneous alcohol intake was observed in the hypothalamus of POMC mRNA. Increased. And beta endorphin-like peptide was significantly increased. However, DBA / 2 did not alter the activity of the beta-endorphin system (De Waele J, Gianoulakis C: Enhanced activity of the brain β-endorphin system by free-choice ethanol drinking in C57BL / 6 but not DBA / 2 mice, European Journal of Pharmacology, 258 (1-2): 119-129, 1994). Compared with ANA rats with low alcohol consumption and POMC mRNA expression, AA rats, which are characterized by high impulsive behavior, showed higher tendency in AA rats (Lindblom J, Wikberg JE, Bergstrom L: Alcohol-preferring AA rats). s-how a derangement in their central melanocortin signaling system, Pharmacol Biochem Behav, 72 (1-2): 491-496, 2002). In addition, AA rats contained 52% higher amounts of POMC mRNA in the arch nucleus than ANA rats, and proopiomelanocortin, proenkephalin, and prodinor were administered to ANA rats and AA rats through in situ hybridization. Comparing the pin mRNA, AA mice showed significantly higher proopiomelanocortin mRNA in the hypothalamic arch nucleus, proenkephalin mRNA in the frontal cortex, and prodinorphine mRNA in the medial dorsal cortex (Marinelli). PW, Kiianmaa K, Gianoulakis C: Opioid propeptide mRNA content and receptor density in the brains of AA and ANA rats, Life Scie-nces, 66 (20): 1915-1927, 2000). In clinical studies, blood was collected from 12 chronic alcoholics and 12 nonalcoholics, indicating a significant increase in POMC mRNA in chronic alcoholics (Rosenberger P, Muhlbauer E, Weissmuller T, Rommelspacher H, Sinha P). , Wernecke KD, Finckh U, Rettig J, Kox WJ, Spies CD: Decreased proopiomelanocortin mRNA in lymphocytes of chronic alcoholics after intravenous human corticotropin releasing factor injection, Alcohol Clin Exp Res, 27 (11): 1693-1700, 2003). Compared with alcoholism and POMC mRNA of control group, it was higher than control group in alcoholic lymphocytes (Winkler A, Schmidt LG, Rommelspacher H, Melzig MF: Quantification of proopiomelanocortin mRNA in peripheral lymphocytes of alcoholics, Alcohol, 15 (1) : 43-50, 1998).
이를 종합해 볼 때, 갈근해주탕은 POMC mRNA 발현을 낮추어 알코올 선호도를 감소시켜, 알코올의 영향을 줄여 알코올의 섭취를 막는다고 해석할 수 있다. Taken together, Galgunju-tang can be interpreted to reduce the alcohol preference by lowering the expression of POMC mRNA, thereby reducing the effect of alcohol to prevent alcohol intake.
도 1은 POMC mRNA 발현 측정 결과를 나타내는 도면이다. *: 1일 GHT-H 투여군의 독립 t-검증(p=0.043). 1 shows POMC mRNA expression measurement results. *: Independent t-test (p = 0.043) of daily GHT-H group.
<110> University-Industry Cooperation Group of Kyung Hee University <120> Composition comprising herbal mixture extract as an active ingredient for prevention and treatment of alcohol dependence <130> 7p-10-41 <160> 2 <170> KopatentIn 1.71 <210> 1 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Forward primer for POMC <400> 1 gattctgcta cagtcgctc 19 <210> 2 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer for POMC <400> 2 gaactctagg ggaaaggc 18 <110> University-Industry Cooperation Group of Kyung Hee University <120> Composition comprising herbal mixture extract as an active ingredient for prevention and treatment of alcohol dependence <130> 7p-10-41 <160> 2 <170> KopatentIn 1.71 <210> 1 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Forward primer for POMC <400> 1 gattctgcta cagtcgctc 19 <210> 2 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer for POMC <400> 2 gaactctagg ggaaaggc 18
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070126128A KR100990710B1 (en) | 2007-12-06 | 2007-12-06 | Composition comprising herbal mixture extract as an active ingredient for prevention and treatment of alcohol dependence |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070126128A KR100990710B1 (en) | 2007-12-06 | 2007-12-06 | Composition comprising herbal mixture extract as an active ingredient for prevention and treatment of alcohol dependence |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090059326A KR20090059326A (en) | 2009-06-11 |
KR100990710B1 true KR100990710B1 (en) | 2010-10-29 |
Family
ID=40989457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070126128A KR100990710B1 (en) | 2007-12-06 | 2007-12-06 | Composition comprising herbal mixture extract as an active ingredient for prevention and treatment of alcohol dependence |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100990710B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012073627A1 (en) * | 2010-12-02 | 2012-06-07 | 丸善製薬株式会社 | Tie2 ACTIVATOR, VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, ANTI-ANGIOGENIC AGENT, AGENT FOR MATURING BLOOD VESSELS, AGENT FOR NORMALIZING BLOOD VESSELS, AGENT FOR STABILIZING BLOOD VESSELS, AND PHARMACEUTICAL COMPOSITION |
KR101379368B1 (en) * | 2012-05-22 | 2014-04-02 | 정진남 | Composition for treating alcohol intoxication containing fructus xanthii extracts and method of preparing the extracts |
-
2007
- 2007-12-06 KR KR1020070126128A patent/KR100990710B1/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
논문2:동의신경정신과* |
Also Published As
Publication number | Publication date |
---|---|
KR20090059326A (en) | 2009-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1964730B (en) | Herbal compositions for prevention and treatment rheumatic and inflammatory diseases and method of preparing the same | |
KR100360674B1 (en) | Herbal composition for preventing and treating dementria | |
CN107753801A (en) | Anti-trioxypurine, drop purine treat pharmaceutical composition of gout and preparation method thereof | |
US6416795B1 (en) | Herbal extract composition for stress prevention and treatment | |
KR101793531B1 (en) | A composition and functional food comprising an combination extract of Atractylodes macrocephala KOIDZ, Morus alba L., Lycium chinensis, Euphoria lingan STEUD, Achyranthus japonica NAKAI, Eucommia ulmoides OLIV and Asparagus cochinchinensis MERR for preventing or treating postmenopause syndrome | |
US20190160136A1 (en) | Solid Beverage for Conditioning Qi Deficiency Constitution and Method for Producing the Same | |
CN101095717A (en) | Agent for improving body immune function | |
US20060269623A1 (en) | Herbal composition and method of use for promoting erections and treating erectile dysfunction in men | |
KR100990710B1 (en) | Composition comprising herbal mixture extract as an active ingredient for prevention and treatment of alcohol dependence | |
KR20170057532A (en) | Composition for body temperature rise with medicinal herbs classified as a food ingredient and Manufacturing method thereof | |
KR100688252B1 (en) | Composition for improving male sexual function | |
CN104248722A (en) | Medicament for treating female hypersexuality | |
CN109223886A (en) | Chinese medicine composition and its preparation method and application for invigorating the spleen to arrest diarrhea | |
CN110755458A (en) | New use of penthorum chinense pursh for preventing and treating renal proteinuria | |
US20100285163A1 (en) | Composition for Treating or Preventing Hot Flashes and use Thereof | |
CN108635492A (en) | A kind of Chinese medicine composition and the preparation method and application thereof of prevention Trichomonad of dove | |
KR100850503B1 (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
KR102038337B1 (en) | A composition for treating or preventing tic disorder or adhd, a composition for improving memory or concentration | |
CN107496503A (en) | A kind of capsule preparations for being used to increase bone density | |
WO2016197878A1 (en) | Pharmaceutical composition for treatment of menopausal syndrome and preparation method thereof | |
JP2005533797A (en) | YIAN decoction for the treatment of drug addiction | |
CN115737777B (en) | Compound anti-alcohol traditional Chinese medicine composition and preparation method thereof | |
CN108653457B (en) | Traditional Chinese medicine composition for treating infantile malnutrition | |
CN104206597B (en) | A kind of schisandra health care tea alleviating YIN-deficiency of the lung and kidney symptom and preparation method thereof | |
CN103520684A (en) | Traditional Chinese medicine compound for reducing blood sugar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130827 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140925 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |